Strong on results.

before Otoscopic view of tympanic membrane in a patient who did not respond to ampicillin

after Same patient after ten days of Bactrim (trimethoprim and sulfamethoxazole/Roche) therapy

Simple to take.

ROCHE®

in acute otitis media

- **Penetrates and clears middle-ear fluid of susceptible strains of *H. influenzae* and *S. pneumoniae*[1]**
- **Reduces evidence of inflammation and bulging eardrum[2]**
- **Results in a reduction of fever, pain and other symptoms[2,3]**

Active against 86% of *H. influenzae in vitro*—even amoxicillin- and ampicillin-resistant strains

Overall, 86% of *Haemophilus influenzae* strains taken from sputum cultures prove susceptible *in vitro* to Bactrim.[4] In one study, 100% of 191 ampicillin-resistant *H. influenzae* isolates were susceptible to Bactrim.[5] However, *in vitro* data do not necessarily correlate with clinical results.

Active against 91% of *S. pneumoniae in vitro*

In sputum cultures of *Streptococcus pneumoniae*, the most frequent pathogen in acute otitis media, 91% of isolates show susceptibility *in vitro* to Bactrim.[4]

Excellent clinical activity—and economical

In comparative clinical trials in children with acute otitis media, Bactrim *b.i.d.* was unsurpassed by ampicillin, amoxicillin or cefaclor.[6]
And the average cost of Bactrim is lower than that of cefaclor and comparable to that of ampicillin and amoxicillin.[7]
Bactrim is indicated in acute otitis media due to susceptible organisms when it offers an advantage over other antimicrobials. Bactrim is contraindicated in pregnancy, lactation, infants under two months of age and documented megaloblastic anemia due to folate deficiency. To date, there are limited data on the safety of repeated use of Bactrim in children under two years of age.

Cherry-flavored suspension

Bactrim™ Pediatric

(trimethoprim and sulfamethoxazole/Roche)

B.I.D. for enhanced compliance.

Please see references and summary of product information on following page.

References: 1. Klimek JJ *et al*: *J Pediatr* 96:1087-1089, Jun 1980. 2. Schwartz RH *et al*: *Rev Infect Dis* 4:514-516, Mar-Apr 1982. 3. Cooper J, Inman JS, Dawson AF: *Practitioner* 217:804-809, Nov 1976. 4. Antibiotic Sensitivity Report, Winter 1983. BAC-DATA Medical Information Systems, Inc. 5. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. 6. Wormser GP, Keusch GT, Heel RC: *Drugs* 24:459-518, Dec 1982. 7. *Med Lett Drugs Ther* 23:93-95, Oct 30, 1981.



Sexuality & Reproduction for the Cancer Patient

A one-day symposium for physicians and allied health professionals.

April 19, 1985

Featuring guest speakers...

Ramona Chapman, MD
Director, Chapman
Regional Cancer Ctr.
Joplin, Missouri

William H. Masters, MD
Founder, Masters and
Johnson Institute
St. Louis, Missouri

Cappy Rothman, MD
Board Certified
Urologist
Los Angeles, California

6 hours of Category I Continuing Medical Education credit available.

For reservations and information call (415) 674-2359.

4th Annual Cancer Symposium

MT. DIABLO HOSPITAL
REGIONAL CANCER CENTER
Concord, California

SORBITRATE®
(ISOSORBIDE DINITRATE)

Please consult full prescribing information before use. A summary follows:

INDICATIONS AND USAGE: SORBITRATE (isosorbide dinitrate) is indicated for the treatment and prevention of angina pectoris. All dosage forms of isosorbide dinitrate may be used prophylactically to decrease frequency and severity of anginal attacks and can be expected to decrease the need for sublingual nitroglycerin.

The sublingual and chewable forms of the drug are indicated for acute prophylaxis of angina pectoris when taken a few minutes before situations likely to provoke anginal attacks. Because of a slower onset of effect, the oral forms of isosorbide dinitrate are not indicated for acute prophylaxis.

CONTRAINDICATIONS: SORBITRATE is contraindicated in patients who have shown purported hypersensitivity or idiosyncrasy to it or other nitrates or nitrites. Epinephrine and related compounds are ineffective in reversing the severe hypotensive events associated with overdose and are contraindicated in this situation.

WARNINGS: The benefits of SORBITRATE during the early days of an acute myocardial infarction have not been established. If one elects to use organic nitrates in early infarction, hemodynamic monitoring and frequent clinical assessment should be used because of the potential deleterious effects of hypotension.

PRECAUTIONS: General: Severe hypotensive response, particularly with upright posture, may occur with even small doses of SORBITRATE. The drug should therefore be used with caution in subjects who may have blood volume depletion from diuretic therapy or in subjects who have low systolic blood pressure (eg, below 90 mmHg). Paradoxical bradycardia and increased angina pectoris may accompany nitrate-induced hypotension. Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.

Marked symptomatic, orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustment of either class of agents may be necessary.

Tolerance to this drug and cross-tolerance to other nitrates and nitrites may occur. Tolerance to the vascular and antianginal effects of isosorbide dinitrate or nitroglycerin has been demonstrated in clinical trials, experience through occupational exposure, and in isolated tissue experiments in the laboratory. The importance of tolerance to the appropriate use of isosorbide dinitrate in the management of patients with angina pectoris has not been determined. However, one clinical trial using treadmill exercise tolerance (as an end point) found an 8-hour duration of action of oral isosorbide dinitrate following the first dose (after a 2-week placebo washout) and only a 2-hour duration of effect of the same dose after 1 week of repetitive dosing at conventional dosing intervals. On the other hand, several trials have been able to differentiate isosorbide dinitrate from placebo after 4 weeks of therapy and, in open trials, an effect seems detectable for as long as several months.

Tolerance clearly occurs in industrial workers continuously exposed to nitroglycerin. Moreover, physical dependence also occurs since chest pain, acute myocardial infarction, and even sudden death have occurred during temporary withdrawal of nitroglycerin from the workers. In clinical trials in angina patients, there are reports of anginal attacks being more easily provoked and of rebound in the hemodynamic effects soon after nitrate withdrawal. The relative importance of these observations to the routine, clinical use of isosorbide dinitrate is not known. However, it seems prudent to gradually withdraw patients from isosorbide dinitrate when the therapy is being terminated, rather than stopping the drug abruptly.

Information for Patients: Headache may occur during initial therapy with SORBITRATE. Headache is usually relieved by the use of standard headache remedies or by lowering the dose and tends to disappear after the first week or two of use.

Drug Interactions: Alcohol may enhance any marked sensitivity to the hypotensive effect of nitrates.

Isosorbide dinitrate acts directly on vascular smooth muscle; therefore, any other agent that depends on vascular smooth muscle as the final common path can be expected to have decreased or increased effect depending on the agent.

Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term studies in animals have been performed to evaluate the carcinogenic potential of this drug. A modified two-litter reproduction study in rats fed isosorbide dinitrate at 25 or 100 mg/kg/day did not reveal any effects on fertility or gestation or any remarkable gross pathology in any parent or offspring fed isosorbide dinitrate as compared with rats fed a basal-controlled diet.

Pregnancy Category C: Isosorbide dinitrate has been shown to cause a dose-related increase in embryotoxicity (increase in mummified pups) in rabbits at oral doses 35 and 150 times the maximum recommended human daily dose. There are no adequate and well-controlled studies in pregnant women. SORBITRATE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SORBITRATE is administered to a nursing woman.

Pediatric Use: The safety and effectiveness of SORBITRATE in children has not been established.

ADVERSE REACTIONS: Adverse reactions, particularly headache and hypotension, are dose-related. In clinical trials at various doses, the following have been observed:

Headache is the most common (reported incidence varies widely, apparently being dose-related, with an average occurrence of about 25%) adverse reaction and may be severe and persistent. Cutaneous vasodilation with flushing may occur. Transient episodes of dizziness and weakness, as well as other signs of cerebral ischemia associated with postural hypotension, may occasionally develop (the incidence of reported symptomatic hypotension ranges from 2% to 36%). An occasional individual will exhibit marked sensitivity to the hypotensive effects of nitrates and severe responses (nausea, vomiting, weakness, restlessness, pallor, perspiration, and collapse) may occur even with the usual therapeutic dose. Drug rash and/or exfoliative dermatitis may occasionally occur. Nausea and vomiting appear to be uncommon. Case reports of clinically significant methemoglobinemia are rare at conventional doses of organic nitrates. The formation of methemoglobin is dose-related and, in the case of genetic abnormalities of hemoglobin that favor methemoglobin formation, even conventional doses of organic nitrate could produce harmful concentrations of methemoglobin.

DOSAGE AND ADMINISTRATION: For the treatment of angina pectoris, the usual starting dose for sublingual SORBITRATE is 2.5 to 5 mg; for chewable tablets, 5 mg; for oral (swallowed) tablets, 5 to 20 mg; and for controlled-release forms, 40 mg.

SORBITRATE should be titrated upward until angina is relieved or side effects limit the dose. In ambulatory patients, the magnitude of the incremental dose increase should be guided by measurements of standing blood pressure.

The initial dosage of sublingual or chewable SORBITRATE for prophylactic therapy in angina pectoris patients is generally 5 or 10 mg every 2 to 3 hours. Adequate controlled clinical studies demonstrating the effectiveness of chronic maintenance therapy with these dosage forms have not been reported.

SORBITRATE in oral doses of 10 to 40 mg given every 6 hours or in oral controlled-release doses of 40 to 80 mg given every 8 to 12 hours is generally recommended. The extent to which development of tolerance should modify the dosage program has not been defined. *The oral controlled-release forms of isosorbide dinitrate should not be chewed.*

DOSAGE FORMS AVAILABLE: Sublingual Tablets (2.5, 5, 10 mg); Chewable Tablets (5, 10 mg); Oral Tablets (5, 10, 20, 30, 40 mg); Sustained Action Tablets (40 mg).

STUART PHARMACEUTICALS
Division of ICI Americas Inc.
Wilmington, DE 19897

See following page.

Angina comes in many forms...

So does

SORBITRATE®

(ISOSORBIDE DINITRATE)

Unsurpassed flexibility in nitrate therapy.

See previous page for brief summary of prescribing information.

CORGARD®
(nadolol tablets)

40 mg, 80 mg, 120 mg, and 160 mg
easy-to-break scored tablets

ONCE A DAY FOR HYPERTENSION



CORGARD® TABLETS
Nadolol Tablets

DESCRIPTION: Corgard (nadolol) is a synthetic nonselective beta-adrenergic receptor blocking agent.

CONTRAINDICATIONS: Bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see WARNINGS).

WARNINGS: Cardiac Failure—Sympathetic stimulation may be a vital component supporting circulatory function in congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure; therefore, at first sign or symptom of heart failure, digitalize and/or give diuretics, and closely observe response, or discontinue nadolol (gradually if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal— Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after *abrupt* discontinuation of such therapy. When discontinuing chronic use of nadolol, particularly in patients with ischemic heart disease, gradually reduce dosage over a 1- to 2-week period and carefully monitor the patient. Reinstitute nadolol promptly (at least temporarily) and take other measures appropriate for management of unstable angina if angina markedly worsens or acute coronary insufficiency develops. Warn patients not to interrupt or discontinue therapy without physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)— PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Administer nadolol with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of $beta_2$ receptors.

Major Surgery—Because beta blockade impairs the ability of the heart to respond to reflex stimuli and may increase risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, withdraw beta-blockers well before surgery takes place. In emergency surgery, inform the anesthesiologist that the patient is on beta-blocker therapy. Use of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levarterenol can reverse the effects of nadolol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents.

Diabetes and Hypoglycemia—Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust dose of antidiabetic drugs.

Thyrotoxicosis—Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. To avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm, carefully manage patients suspected of developing thyrotoxicosis.

PRECAUTIONS: Impaired Hepatic or Renal Function—Use nadolol with caution in presence of either of these conditions (see DOSAGE AND ADMINISTRATION section of package insert).

Information for Patients—Warn patients, especially those with evidence of coronary artery insufficiency, against interruption or discontinuation of nadolol without physician's advice. Although cardiac failure rarely occurs in properly selected patients, advise patients being treated with beta-adrenergic blocking agents to consult physician at first sign or symptom of impending failure.

Drug Interactions—Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. When treating patients with nadolol plus a catecholamine-depleting agent, carefully observe for evidence of hypotension and/or excessive bradycardia which may produce vertigo, syncope, or postural hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility—In 1 to 2 years' oral toxicologic studies in mice, rats, and dogs, nadolol did not produce significant toxic effects. In 2-year oral carcinogenic studies in rats and mice, nadolol did not produce neoplastic, preneoplastic, or nonneoplastic pathologic lesions.

Pregnancy—In animal reproduction studies with nadolol, evidence of embryo-and fetotoxicity was found in rabbits (but not in rats or hamsters) at doses 5 to 10 times greater (on a mg/kg basis) than maximum indicated human dose; no teratogenic potential was seen in any of these species. There are no well-controlled studies in pregnant women; therefore, use nadolol in pregnant women only if potential benefit justifies potential risk to the fetus.

Nursing Mothers—It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when nadolol is administered to a nursing woman. Animal studies showed that nadolol is found in the milk of lactating rats.

Pediatric Use—Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Most adverse effects have been mild and transient and have rarely required nadolol withdrawal.

Cardiovascular—Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). **Central Nervous System**—Dizziness or fatigue reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior reported in approximately 6 of 1000 patients. **Respiratory**—Bronchospasm reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS). **Gastrointestinal**— Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence each reported in 1 to 5 of 1000 patients. **Miscellaneous**—Each of the following reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Although relationship to drug usage is not clear, sleep disturbances have been reported. The oculomucocutaneous syndrome associated with practolol has not been reported with nadolol.

Potential Adverse Effects: Although other adverse effects reported with other beta-adrenergic blocking agents have not been reported with nadolol, they should be considered potential adverse effects of nadolol. **Central Nervous System**—reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place; short-term memory loss, emotional lability with slightly clouded sensorium; decreased performance on neuropsychometrics. **Gastrointestinal**—mesenteric arterial thrombosis; ischemic colitis. **Hematologic**—agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura. **Allergic**—fever combined with aching and sore throat; laryngospasm; respiratory distress. **Miscellaneous**—reversible alopecia; Peyronie's disease; erythematous rash.

OVERDOSAGE: Nadolol can be removed from the general circulation by hemodialysis. In addition to gastric lavage, employ the following measures as appropriate. In determining duration of corrective therapy, take note of long duration of effect of nadolol.

Excessive Bradycardia—Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.

Cardiac Failure—Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.

Hypotension—Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.)

Bronchospasm—Administer a $beta_2$-stimulating agent and/or a theophylline derivative.

DOSAGE: For all patients, DOSAGE MUST BE INDIVIDUALIZED.

For **angina pectoris,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments at 3 to 7 day intervals until optimum clinical response or pronounced slowing of the heart rate; usual maintenance dose is 80 to 240 mg q.d. (most patients respond to 160 mg or less daily). If treatment is to be discontinued, reduce dosage gradually over a period of 1 to 2 weeks (see WARNINGS).

For **hypertension,** usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments until optimum blood pressure reduction is achieved; usual maintenance dose is 80 to 320 mg q.d. (rarely, doses up to 640 mg may be needed).

Patients with renal failure require adjustment in dosing interval; see package insert for dosage in these patients.

For full prescribing information, consult package insert.

HOW SUPPLIED: In scored tablets containing 40, 80, 120, or 160 mg nadolol per tablet in bottles of 100 and 1000 tablets and in Unimatic® unit-dose packs of 100 tablets.

SQUIBB
Innovators in cardiovascular medicine

514-519

Issued: June 1984

The Joint National Committee now advocates beta-blockers for broad Step-1 usage

IN HYPERTENSION CORGARD® (nadolol tablets)

BLOCKS BETA RECEPTORS IN THE HEART WHILE APPARENTLY PRESERVING RENAL BLOOD FLOW



Effect on kidney

"...investigations suggest that the long-term use of nadolol, a long-acting nonselective agent, is associated with preserved renal function."[1]

"...the majority of investigators utilizing propranolol have reported decrements in RPF [renal plasma flow] and GFR [glomerular filtration rate]..."[1]

CORGARD® (nadolol tablets) should be used with caution in patients with impaired renal function.

Reference: 1. Epstein M, Oster JR: Beta-blockers and the kidney. Mineral Electrolyte Metab 8: 237-254, 1982.

SQUIBB®
Innovators in cardiovascular medicine

TAKE THE ADVANTAGE TO HEART

Please see the adjacent page of this advertisement for brief summary.

Upjohn

The Upjohn Company Kalamazoo, Michigan 49001

Medrol® Dosepak® Unit-of-Use

4 mg methylprednisolone tablets, USP

The explicit printed dosage instructions that accompany each *Dosepak* make it easy for the patient to understand and follow the dosage regimen.



J-9305

For Southern California physicians only

DOCTORS AND LAWYERS FINALLY AGREE ON SOMETHING.

After a thorough examination of the competition, thousands of doctors chose Alpha Micro computer systems.

As for the system itself, it takes you from one to over forty users without changing software, makes it easy to add to your files, lets different people do different things at the same time, and makes complex tasks seem far less complex.

Call us. We'll tell you why so many business people have chosen Alpha Micro over all the others.

We think you'll agree. **ALPHA MICRO**



Zybex's acclaimed powerful CYBERMED software has been installed with Alpha Micro computers for more than seven years in Southern California. For your convenience, please call toll free 800-328-2211.

ZYBEX

Computer and Business Systems

367 Bird Rock Ave.
La Jolla, CA 92037
(619)459-2797

(800)328-2211

2618 W. Main Street
Alhambra, CA 91801
(818)281-3696



"When it comes to cardiovascular medicine, I like to know exactly what my patients are swallowing."

There are doctors who say that generic drugs have a place in their practice—but not necessarily in the treatment of serious or potentially life-threatening disease. And when they consider that the average patient pays only about 45¢ a day for INDERAL (propranolol HCl) Tablets, there's not much left to discuss.

When it's INDERAL Tablets you want for the treatment of hypertension, angina, arrhythmias, or post-MI patients, make sure you specify "Dispense As Written" (DAW), "Do Not Substitute," or whatever is required in your State. That way, you'll know exactly what your patients will get.

Please see next page for brief summary of prescribing information.

"When it comes to cardiovascular medicine, I like to know exactly what my patients are swallowing."

INDERAL® Tablets

BRAND OF PROPRANOLOL HCl



10 mg 20 mg 40 mg 60 mg 80 mg 90 mg*

BRIEF SUMMARY (FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE CIRCULAR.)

INDERAL® (propranolol hydrochloride) Tablets

CONTRAINDICATIONS

INDERAL is contraindicated in 1) cardiogenic shock, 2) sinus bradycardia and greater than first degree block, 3) bronchial asthma, 4) congestive heart failure (see WARNINGS) unless the failure is secondary to a tachyarrhythmia treatable with INDERAL.

WARNINGS

CARDIAC FAILURE: Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta blockers should be avoided in overt congestive heart failure, if necessary they can be used with close follow-up in patients with a history of failure who are well compensated and are receiving digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or INDERAL should be discontinued (gradually, if possible).

IN PATIENTS WITH ANGINA PECTORIS, there have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of INDERAL therapy. Therefore, when discontinuance of INDERAL is planned the dosage should be gradually reduced over at least a few weeks and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If INDERAL therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute INDERAL therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)—PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS. INDERAL should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta receptors.

MAJOR SURGERY: The necessity or desirability of withdrawal of beta-blocking therapy prior to major surgery is controversial. It should be noted, however, that the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

INDERAL, like other beta blockers, is a competitive inhibitor of beta-receptor agonists and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Difficulty in starting and maintaining the heartbeat has also been reported with beta blockers.

DIABETES AND HYPOGLYCEMIA: Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute hypoglycemia in labile insulin-dependent diabetes. In these patients, it may be more difficult to adjust the dosage of insulin.

THYROTOXICOSIS: Beta blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol does not distort thyroid function tests.

IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME, several cases have been reported in which, after propranolol, the tachycardia was replaced by a severe bradycardia requiring a demand pacemaker. In one case this resulted after an initial dose of 5 mg propranolol.

PRECAUTIONS

General: Propranolol should be used with caution in patients with impaired hepatic or renal function. INDERAL is not indicated for the treatment of hypertensive emergencies.

Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that INDERAL (propranolol hydrochloride) may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

Clinical Laboratory Tests: Elevated blood urea levels in patients with severe heart disease, elevated serum transaminase, alkaline phosphatase, lactate dehydrogenase.

DRUG INTERACTIONS: Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if INDERAL is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have been conducted to evaluate toxic effects and carcinogenic potential. In 18-month studies in both rats and mice, employing doses up to 150 mg/kg/day, there was no evidence of significant drug-induced toxicity. There were no drug-related tumorigenic effects at any of the dosage levels. Reproductive studies in animals did not show any impairment of fertility that was attributable to the drug.

Pregnancy: Pregnancy Category C. INDERAL has been shown to be embryotoxic in animal studies at doses about 10 times greater than the maximum recommended human dose.

There are no adequate and well-controlled studies in pregnant women. INDERAL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: INDERAL is excreted in human milk. Caution should be exercised when INDERAL is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.

Cardiovascular: bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.

Central Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal: nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.

Allergic: pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm and respiratory distress.

Respiratory: bronchospasm.

Hematologic: agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Auto-Immune: In extremely rare instances, systemic lupus erythematosus has been reported.

Miscellaneous: alopecia, LE-like reactions, psoriasiform rashes, dry eyes, male impotence, and Peyronie's disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.

*The appearance of INDERAL tablets is a registered trademark of Ayerst Laboratories.

9429/185

Ayerst® AYERST LABORATORIES
New York, N.Y. 10017

BALANCED CALCIUM CHANNEL BLOCKER

Low incidence of side effects
CARDIZEM® (diltiazem HCl) produces an incidence of adverse reactions not greater than that reported with placebo therapy, thus contributing to the patient's sense of well-being.

Reduces angina attack frequency*
42% to 46% decrease reported in multicenter study.[1]

Increases exercise tolerance*
In Bruce exercise test,[2] control patients averaged 8.0 minutes to onset of pain; Cardizem patients averaged 9.8 minutes ($P<.005$).

*Cardizem is indicated in the treatment of angina pectoris due to coronary artery spasm and in the management of chronic stable angina (classic effort-associated angina) in patients who cannot tolerate therapy with beta-blockers and/or nitrates or who remain symptomatic despite adequate doses of these agents.

References:
1. Strauss WE, McIntyre KM, Parisi AF, et al: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial. Am J Cardiol 49:560-566, 1982.
2. Pool PE, Seagren SC, Bonanno JA, et al: The treatment of exercise-inducible chronic stable angina with diltiazem: Effect on treadmill exercise. Chest 78 (July suppl):234-238, 1980.

CARDIZEM®
(diltiazem HCl)

THE BALANCED CALCIUM CHANNEL BLOCKER

Please see full prescribing information on following page.

PROFESSIONAL USE INFORMATION

Cardizem® (diltiazem HCl)

30 mg and 60 mg tablets

DESCRIPTION

CARDIZEM® (diltiazem hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1,5-Benzothiazepin-4(5H)one,3-(acetyloxy) -5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+) -cis-. The chemical structure is:



Diltiazem hydrochloride is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol, and chloroform. It has a molecular weight of 450.98. Each tablet of CARDIZEM contains either 30 mg or 60 mg diltiazem hydrochloride for oral administration.

CLINICAL PHARMACOLOGY

The therapeutic benefits achieved with CARDIZEM are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle.

Mechanisms of Action. Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways:

1. Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by CARDIZEM.
2. Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise work loads.

In animal models, diltiazem interferes with the slow inward (depolarizing) current in excitable tissue. It causes excitation-contraction uncoupling in various myocardial tissues without changes in the configuration of the action potential. Diltiazem produces relaxation of coronary vascular smooth muscle and dilation of both large and small coronary arteries at drug levels which cause little or no negative inotropic effect. The resultant increases in coronary blood flow (epicardial and subendocardial) occur in ischemic and nonischemic models and are accompanied by dose-dependent decreases in systemic blood pressure and decreases in peripheral resistance.

Hemodynamic and Electrophysiologic Effects. Like other calcium antagonists, diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations. In the intact animal, prolongation of the AH interval can be seen at higher doses.

In man, diltiazem prevents spontaneous and ergonovine-provoked coronary artery spasm. It causes a decrease in peripheral vascular resistance and a modest fall in blood pressure and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect; cardiac output, ejection fraction, and left ventricular end diastolic pressure have not been affected. There are as yet few data on the interaction of diltiazem and beta-blockers. Resting heart rate is usually unchanged or slightly reduced by diltiazem.

Intravenous diltiazem in doses of 20 mg prolongs AH conduction time and AV node functional and effective refractory periods approximately 20%. In a study involving single oral doses of 300 mg of CARDIZEM in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazem-associated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick sinus syndrome, diltiazem significantly prolongs sinus cycle length (up to 50% in some cases).

Chronic oral administration of CARDIZEM in doses of up to 240 mg/day has resulted in small increases in PR interval, but has not usually produced abnormal prolongation. There were, however, three instances of second-degree AV block and one instance of third-degree AV block in a group of 959 chronically treated patients.

Pharmacokinetics and Metabolism. Diltiazem is absorbed from the tablet formulation to about 80% of a reference capsule and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%. CARDIZEM undergoes extensive hepatic metabolism in which 2% to 4% of the unchanged drug appears in the urine. In vitro binding studies show CARDIZEM is 70% to 80% bound to plasma proteins. Competitive ligand binding studies have also shown CARDIZEM binding is not altered by therapeutic concentrations of digoxin, hydrochlorothiazide, phenylbutazone, propranolol, salicylic acid, or warfarin. Single oral doses of 30 to 120 mg of CARDIZEM result in detectable plasma levels within 30 to 60 minutes and peak plasma levels two to three hours after drug administration. The plasma elimination half-life following single or multiple drug administration is approximately 3.5 hours. Desacetyl diltiazem is also present in the plasma at levels of 10% to 20% of the parent drug and is 25% to 50% as potent a coronary vasodilator as diltiazem. Therapeutic blood levels of CARDIZEM appear to be in the range of 50 to 200 ng/ml. There is a departure from dose-linearity when single doses above 60 mg are given; a 120-mg dose gave blood levels three times that of the 60-mg dose. There is no information about the effect of renal or hepatic impairment on excretion or metabolism of diltiazem.

INDICATIONS AND USAGE

1. **Angina Pectoris Due to Coronary Artery Spasm.** CARDIZEM is indicated in the treatment of angina pectoris due to coronary artery spasm. CARDIZEM has been shown effective in the treatment of spontaneous coronary artery spasm presenting as Prinzmetal's variant angina (resting angina with ST-segment elevation occurring during attacks).
2. **Chronic Stable Angina (Classic Effort-Associated Angina).** CARDIZEM is indicated in the management of chronic stable angina. CARDIZEM has been effective in controlled trials in reducing angina frequency and increasing exercise tolerance.

There are no controlled studies of the effectiveness of the concomitant use of diltiazem and beta-blockers or of the safety of this combination in patients with impaired ventricular function or conduction abnormalities.

CONTRAINDICATIONS

CARDIZEM is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, and (3) patients with hypotension (less than 90 mm Hg systolic).

WARNINGS

1. **Cardiac Conduction.** CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (six of 1243 patients for 0.48%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem.
2. **Congestive Heart Failure.** Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.
3. **Hypotension.** Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.
4. **Acute Hepatic Injury.** In rare instances, patients receiving CARDIZEM have exhibited reversible acute hepatic injury as evidenced by moderate to extreme elevations of liver enzymes. (See PRECAUTIONS and ADVERSE REACTIONS.)

PRECAUTIONS

General. CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any new drug given over prolonged periods, laboratory parameters should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function. In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.

Drug Interaction. Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM. (See WARNINGS).

Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers or digitalis is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities. In healthy volunteers, diltiazem has been shown to increase serum digoxin levels up to 20%.

Carcinogenesis, Mutagenesis, Impairment of Fertility. A 24-month study in rats and a 21-month study in mice showed no evidence of carcinogenicity. There was also no mutagenic response in in vitro bacterial tests. No intrinsic effect on fertility was observed in rats.

Pregnancy. Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies, there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human dose or greater.

There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when CARDIZEM is administered to a nursing woman if the drug's benefits are thought to outweigh its potential risks in this situation.

Pediatric Use. Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded.

In domestic placebo-controlled trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies which can be at least reasonably associated with the pharmacology of calcium influx inhibition. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences, as well as their frequency of presentation, are: edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), asthenia (1.2%), AV block (1.1%). In addition, the following events were reported infrequently (less than 1%) with the order of presentation corresponding to the relative frequency of occurrence.

Cardiovascular:	Flushing, arrhythmia, hypotension, bradycardia, palpitations, congestive heart failure, syncope.
Nervous System:	Paresthesia, nervousness, somnolence, tremor, insomnia, hallucinations, and amnesia.
Gastrointestinal:	Constipation, dyspepsia, diarrhea, vomiting, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH.
Dermatologic:	Pruritus, petechiae, urticaria, photosensitivity.
Other:	Polyuria, nocturia.

The following additional experiences have been noted:

A patient with Prinzmetal's angina experiencing episodes of vasospastic angina developed periods of transient asymptomatic asystole approximately five hours after receiving a single 60-mg dose of CARDIZEM.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: erythema multiforme; leukopenia; and extreme elevations of alkaline phosphatase, SGOT, SGPT, LDH, and CPK. However, a definitive cause and effect between these events and CARDIZEM therapy is yet to be established.

OVERDOSAGE OR EXAGGERATED RESPONSE

Overdosage experience with oral diltiazem has been limited. Single oral doses of 300 mg of CARDIZEM have been well tolerated by healthy volunteers. In the event of overdosage or exaggerated response, appropriate supportive measures should be employed in addition to gastric lavage. The following measures may be considered:

Bradycardia	Administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.
High-Degree AV Block	Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing.
Cardiac Failure	Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics.
Hypotension	Vasopressors (eg, dopamine or levarterenol bitartrate).

Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.

The oral LD_{50}'s in mice and rats range from 415 to 740 mg/kg and from 560 to 810 mg/kg, respectively. The intravenous LD_{50}'s in these species were 60 and 38 mg/kg, respectively. The oral LD_{50} in dogs is considered to be in excess of 50 mg/kg, while lethality was seen in monkeys at 360 mg/kg. The toxic dose in man is not known, but blood levels in excess of 800 ng/ml have not been associated with toxicity.

DOSAGE AND ADMINISTRATION

Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm. Dosage must be adjusted to each patient's needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at one- to two-day intervals until optimum response is obtained. Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 to 240 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.

Concomitant Use With Other Antianginal Agents:

1. **Sublingual NTG** may be taken as required to abort acute anginal attacks during CARDIZEM therapy.
2. **Prophylactic Nitrate Therapy**—CARDIZEM may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
3. **Beta-blockers.** (See WARNINGS and PRECAUTIONS.)

HOW SUPPLIED

Cardizem 30-mg tablets are supplied in bottles of 100 (NDC 0088-1771-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1771-49). Each green tablet is engraved with MARION on one side and 1771 engraved on the other. CARDIZEM 60-mg scored tablets are supplied in bottles of 100 (NDC 0088-1772-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1772-49). Each yellow tablet is engraved with MARION on one side and 1772 on the other.

Issued 4/1/84

Another patient benefit product from

PHARMACEUTICAL DIVISION
MARION LABORATORIES, INC.
KANSAS CITY, MISSOURI 64137



THE ENDOCRINOLOGY OF AGING
Three profiles

VASOMOTOR SYMPTOMS THAT DEMAND INTERVENTION



PREMARIN RELIEVES MODERATE TO SEVERE VASOMOTOR SYMPTOMS

Vasomotor symptoms are the most common manifestation of the menopause, affecting up to 75% of menopausal women. Of these, 80% may suffer for more than a year and up to 50% for more than five years.[1] These symptoms can disrupt a woman's life by chronically interrupting sleep, resulting in anxiety and irritability.

In a study of postmenopausal women suffering severe episodes of cutaneous flushing, symptoms improved markedly after administration of estrogen[2]—the treatment of choice for moderate to severe vasomotor symptoms.[3] The estrogen of choice is PREMARIN, the most widely prescribed estrogen for over 40 years. PREMARIN (Conjugated Estrogens Tablets, U.S.P.) relieves moderate to severe vasomotor symptoms of the natural menopause, as well as the acute and often severe symptoms of surgical menopause.

PREMARIN®
(CONJUGATED ESTROGENS TABLETS, U.S.P.)



0.3 mg 0.625 mg 0.9 mg 1.25 mg 2.5 mg

Please see last page for brief summary of full prescribing information.

VAGINAL ATROPHY THAT INTERFERES WITH SEXUALITY



PREMARIN RESTORES THE VAGINAL ENVIRONMENT

In the postmenopausal woman, decreasing levels of estrogen can have devastating effects on a woman's sexual functioning. The pH of vaginal secretions rises, promoting the growth of contaminating organisms. The vaginal epithelium dries and thins, becoming susceptible to irritation, injury, and infection. Sexual relations may be difficult or impossible.

PREMARIN (Conjugated Estrogens, U.S.P.) Vaginal Cream focuses therapy at the site of the problem. Vaginal dryness is relieved, pH reverts to its normal acidity, and the epithelium thickens and becomes more resistant to injury and infection. With the vaginal environment returned to its premenopausal state, sexual function may improve.

PREMARIN®

(CONJUGATED ESTROGENS, U.S.P.) Vaginal Cream



0.625 mg/g

Please see last page for brief summary of full prescribing information.

POSTMENOPAUSAL BONE LOSS THAT INCAPACITATES



PREMARIN MAY HALT THE DISABLING COURSE OF OSTEOPOROSIS*

Osteoporosis has an enormous epidemiological impact: it affects 10 million American women, and 26% of all women over age 60.[5] The disease begins silently and progresses inexorably for 15 to 20 years, until disabling complications occur.[6]

To minimize osteoporotic damage, the condition must be detected early and treated promptly. For many patients, PREMARIN is optimal therapy for osteoporosis, as part of a comprehensive program that includes exercise, good nutrition, and calcium supplements. In a controlled study of postmenopausal and oophorectomized women, PREMARIN (Conjugated Estrogens Tablets, U.S.P.) doses of 0.625 mg/day prevented loss of metacarpal mineral content (see graph above).

PREMARIN®
(CONJUGATED ESTROGENS TABLETS, U.S.P.)



0.3 mg 0.625 mg 0.9 mg 1.25 mg 2.5 mg

*Conjugated Estrogens Tablets have been evaluated as probably effective for treating estrogen-deficiency-induced osteoporosis.

Please see last page for brief summary of full prescribing information.

BRIEF SUMMARY *(FOR FULL PRESCRIBING INFORMATION AND PATIENT INFORMATION, SEE PACKAGE CIRCULAR)*

PREMARIN® Brand of Conjugated Estrogens Tablets, U.S.P.
PREMARIN® Brand of Conjugated Estrogens, U.S.P. Vaginal Cream in a nonliquefying base

1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA.

Three independent case control studies have reported an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for more than one year. This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade. The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment and on estrogen dose. In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study suggests that cyclic administration of low doses of estrogen may carry less risk than continuous administration; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy. There is no evidence at present that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equiestrogenic doses.

2. ESTROGENS SHOULD NOT BE USED DURING PREGNANCY.

The use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, have an increased risk of developing in later life a form of vaginal or cervical cancer that is ordinarily extremely rare. This risk has been estimated as not greater than 4 per 1000 exposures. Furthermore, a high percentage of such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis, epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes. Several reports suggest an association between intrauterine exposure to female sex hormones and congenital anomalies, including congenital heart defects and limb reduction defects. One case control study estimated a 4.7-fold increased risk of limb reduction defects in infants exposed in utero to sex hormones (oral contraceptives, hormone withdrawal tests for pregnancy, or attempted treatment for threatened abortion). Some of these exposures were very short and involved only a few days of treatment. The data suggest that the risk of limb reduction defects in exposed fetuses is somewhat less than 1 per 1000. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progestogens are effective for these uses. If PREMARIN is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.

DESCRIPTION: PREMARIN (Conjugated Estrogens, U.S.P.) contains a mixture of estrogens, obtained exclusively from natural sources, blended to represent the average composition of material derived from pregnant mares' urine. It contains estrone, equilin, and 17α-dihydroequilin, together with smaller amounts of 17α-estradiol, equilenin, and 17α-dihydroequilenin as salts of their sulfate esters.

INDICATIONS: Based on a review of PREMARIN Tablets by the National Academy of Sciences—National Research Council and/or other information, FDA has classified the indications for use as follows:

Effective: 1. Moderate to severe vasomotor symptoms associated with the menopause. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.)
2. Atrophic vaginitis
3. Kraurosis vulvae
4. Female hypogonadism
5. Female castration
6. Primary ovarian failure
7. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
8. Prostatic carcinoma—palliative therapy of advanced disease.
9. Postpartum breast engorgement—Although estrogens have been widely used for the prevention of postpartum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.

PREMARIN HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).

"Probably" effective: For estrogen deficiency-induced osteoporosis, and only when used in conjunction with other important therapeutic measures such as diet, calcium, physiotherapy, and good general health-promoting measures. Final classification of this indication requires further investigation.

INDICATIONS: PREMARIN (Conjugated Estrogens, U.S.P.) Vaginal Cream is indicated in the treatment of atrophic vaginitis and kraurosis vulvae. PREMARIN Vaginal Cream HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).

CONTRAINDICATIONS: Estrogens should not be used in women (or men) with any of the following conditions: 1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2. Known or suspected estrogen-dependent neoplasia. 3. Known or suspected pregnancy (See Boxed Warning). 4. Undiagnosed abnormal genital bleeding. 5. Active thrombophlebitis or thromboembolic disorders. 6. A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast or prostatic malignancy).

WARNINGS: Long term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, cervix, vagina, and liver. There are now reports that estrogens increase the risk of carcinoma of the endometrium in humans. (See Boxed Warning.) At the present time there is no satisfactory evidence that estrogens given to postmenopausal women increase the risk of cancer of the breast, although a recent study has raised this possibility. There is a need for caution in prescribing estrogens for women with a strong family history of breast cancer or who have breast nodules, fibrocystic disease, or abnormal mammograms. A recent study has reported a 2- to 3-fold increase in the risk of surgically confirmed gallbladder disease in women receiving postmenopausal estrogens.

Adverse effects of oral contraceptives may be expected at the larger doses of estrogen used to treat prostatic or breast cancer or postpartum breast engorgement; it has been shown that there is an increased risk of thrombosis in men receiving estrogens for prostatic cancer and women for postpartum breast engorgement. Users of oral contraceptives have an increased risk of diseases, such as thrombophlebitis, pulmonary embolism, stroke, and myocardial infarction. Cases of retinal thrombosis, mesenteric thrombosis, and optic neuritis have been reported in oral contraceptive users. An increased risk of postsurgery thromboembolic complications has also been reported in users of oral contraceptives. If feasible, estrogen should be discontinued at least 4 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. Estrogens should not be used in persons with active thrombophlebitis, thromboembolic disorders, or in persons with a history of such disorders in association with estrogen use. They should be used with caution in patients with cerebral vascular or coronary artery disease. Large doses (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast have been shown to increase the risk of nonfatal myocardial infarction, pulmonary embolism and thrombophlebitis. When doses of this size are used, any of the thromboembolic and thrombotic adverse effects should be considered a clear risk.

Benign hepatic adenomas should be considered in estrogen users having abdominal pain and tenderness, abdominal mass, or hypovolemic shock. Hepatocellular carcinoma has been reported in women taking estrogen-containing oral contraceptives. Increased blood pressure may occur with use of estrogens in the menopause and blood pressure should be monitored with estrogen use. A worsening of glucose tolerance has been observed in patients on estrogen-containing oral contraceptives. For this reason, diabetic patients should be carefully observed. Estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases.

PRECAUTIONS: Physical examination and a complete medical and family history should be taken prior to the initiation of any estrogen therapy with special reference to blood pressure, breasts, abdomen, and pelvic organs, and should include a Papanicolau smear. As a general rule, estrogen should not be prescribed for longer than one year without another physical examination being performed. Conditions influenced by fluid retention such as asthma, epilepsy, migraine, and cardiac or renal dysfunction, require careful observation. Certain patients may develop manifestations of excessive estrogenic stimulation, such as abnormal or excessive uterine bleeding, mastodynia, etc. Prolonged administration of unopposed estrogen therapy has been reported to increase the risk of endometrial hyperplasia in some patients. Oral contraceptives appear to be associated with an increased incidence of mental depression. Patients with a history of depression should be carefully observed. Preexisting uterine leiomyomata may increase in size during estrogen use. The pathologist should be advised of estrogen therapy when relevant specimens are submitted. If jaundice develops in any patient receiving estrogen, the medication should be discontinued while the cause is investigated. Estrogens should be used with care in patients with impaired liver function, renal insufficiency, metabolic bone diseases associated with hypercalcemia, or in young patients in whom bone growth is not complete.

The following changes may be expected with larger doses of estrogen:

a. Increased sulfobromophthalein retention.

b. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.

c. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered.

d. Impaired glucose tolerance.

e. Decreased pregnanediol excretion.

f. Reduced response to metyrapone test.

g. Reduced serum folate concentration.

h. Increased serum triglyceride and phospholipid concentration.

As a general principle, the administration of any drug to nursing mothers should be done only when clearly necessary since many drugs are excreted in human milk.

ADVERSE REACTIONS: The following have been reported with estrogenic therapy, including oral contraceptives: breakthrough bleeding, spotting, change in menstrual flow; dysmenorrhea; premenstrual-like syndrome; amenorrhea during and after treatment; increase in size of uterine fibromyomata; vaginal candidiasis, change in cervical erosion and in degree of cervical secretion; cystitis-like syndrome; tenderness, enlargement, secretion (of breasts); nausea, vomiting, abdominal cramps, bloating; cholestatic jaundice; chloasma or melasma which may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; steepening of corneal curvature; intolerance to contact lenses; headache, migraine, dizziness, mental depression, chorea; increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; changes in libido.

ACUTE OVERDOSAGE: May cause nausea, and withdrawal bleeding may occur in females.

DOSAGE AND ADMINISTRATION:

PREMARIN® Brand of Conjugated Estrogens Tablets, U.S.P.

1. *Given cyclically for short-term use only.* For treatment of moderate to severe *vasomotor* symptoms, atrophic vaginitis, or kraurosis vulvae associated with the menopause (0.3 to 1.25 mg or more daily).

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.

Administration should be cyclic (*e.g.*, three weeks on and one week off).

Attempts to discontinue or taper medication should be made at three to six month intervals.

2. *Given cyclically:* Female hypogonadism. Female castration. Primary ovarian failure. Osteoporosis.

Female hypogonadism – 2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days' duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on the responsiveness of the endometrium.

If bleeding occurs before the end of the 10 day period, begin a 20 day estrogen-progestin cyclic regimen with PREMARIN (Conjugated Estrogens Tablets, U.S.P.), 2.5 to 7.5 mg daily in divided doses, for 20 days. During the last five days of estrogen therapy, give an oral progestin. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding.

Female castration and primary ovarian failure—1.25 mg daily, cyclically. Adjust upward or downward according to response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control.

Osteoporosis (to retard progression)—1.25 mg daily, cyclically.

3. *Given for a few days:* Prevention of postpartum breast engorgement—3.75 mg every four hours for five doses, or 1.25 mg every four hours for five days.

4. *Given chronically:* Inoperable progressing prostatic cancer—1.25 to 2.5 mg three times daily.

Inoperable progressing breast cancer in appropriately selected men and postmenopausal women—10 mg three times daily for a period of at least three months.

Patients with an intact uterus should be monitored for signs of endometrial cancer and appropriate measures taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.

PREMARIN® Brand of Conjugated Estrogens, U.S.P. Vaginal Cream

Given cyclically for short-term use only. For treatment of atrophic vaginitis or kraurosis vulvae.

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.

Administration should be cyclic (*e.g.*, three weeks on and one week off).

Attempts to discontinue or taper medication should be made at three to six month intervals.

Usual dosage range: 2 to 4 g daily, intravaginally or topically, depending on the severity of the condition.

Treated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.

HOW SUPPLIED: PREMARIN (Conjugated Estrogens Tablets, U.S.P.). No. 865—Each *purple* tablet contains 2.5 mg in bottles of 100 and 1,000. No. 866—Each *yellow* tablet contains 1.25 mg in bottles of 100 and 1,000. Also in Cycle Pack of 21 and in unit dose package of 100. No. 864—Each *white* tablet contains 0.9 mg in bottles of 100. Also in Cycle Pack of 21. No. 867—Each *maroon* tablet contains 0.625 mg in bottles of 100 and 1,000. Also in Cycle Pack of 21 and unit dose package of 100. No. 868—Each *green* tablet contains 0.3 mg in bottles of 100 and 1,000. The appearance of these tablets is a trademark of Ayerst Laboratories.

PREMARIN (Conjugated Estrogens, U.S.P.) Vaginal Cream—No. 872—Each gram contains 0.625 mg Conjugated Estrogens, U.S.P. (Also contains cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, phenylethyl alcohol, sodium lauryl sulfate, glycerin, and mineral oil.)

Combination package: Each contains Net Wt. 1½ oz. (42.5 g) tube with one calibrated plastic applicator.

Also Available—Refill package: Each contains Net Wt. 1½ oz. (42.5 g) tube. **4340/285**

References: 1. Judd HL: After the menopause. *Transition* 1983;1:19-30. **2.** Erlik Y, Tataryn IV, Meldrum DR, et al: Association of waking episodes with menopausal hot flushes. *JAMA* 1981;245:1741-1744. **3.** Meldrum DR: The pathophysiology of postmenopausal symptoms. *Sem Reprod Endocrinol* 1983;1(February):11-17. **4.** Lindsay R, Hart DM, Clark DM: The minimum effective dose of estrogen for prevention of postmenopausal bone loss. *Obstet Gynecol* 1984;63:759-763. **5.** Katz WA: *Rheumatic Diseases: Diagnosis and Management*. Philadelphia, JB Lippincott Co, 1977, p 672. **6.** Reese WD: A better way to screen for osteoporosis. *Contemp Ob/Gyn* 1983;22(November):116-131.

Ayerst® AYERST LABORATORIES
New York, N.Y. 10017



The RU-TUSS® Family of Products

Liquid... Expectorant...with Hydrocodone... Tablets... Capsules

Boots Pharmaceuticals, Inc.
6540 LINE AVENUE, P.O. BOX 6750
SHREVEPORT, LOUISIANA 71106-9989

No matter what the season, you can depend on the RU-TUSS® Weather Service for a live, up-to-the-minute weather report anywhere in the United States. Contact your Boots Representative for toll-free access.

Arthritis pain after 50

Age is no barrier to the benefits of Motrin 600 mg tablets

The pain-relieving power of *Motrin* 600 mg tablets is welcome at any age. The advantages of *Motrin* become more important as patients grow older.

Advanced age has little or no influence on the pharmacokinetics of *Motrin.*

Motrin is as effective as indomethacin in relieving arthritis pain and inflammation. *Motrin* causes significantly fewer CNS effects and about half as many GI complaints as indomethacin.

Motrin relieves pain as effectively as a combination of aspirin 650 mg plus codeine 60 mg, as documented in analgesia studies.

Motrin has no significant effect on clotting factors in patients on coumarin-type anticoagulants in controlled studies. *Motrin* should be used with caution in persons with intrinsic coagulation defects and in those on anticoagulant therapy.

Motrin is rapidly metabolized and does not accumulate. *Motrin* provides better control of therapy, rapid response to dosage adjustment, and permits tailoring dosage to each patient's needs.



New: The Motrin Patient Brochure
An easy-to-read booklet, provided to physicians, that helps patients understand their arthritis therapy... encourages their cooperation.

Helping you to help your patients—
Ask your Upjohn Representative for a complimentary supply.

The confidence that comes from experience...good reason to prescribe

Motrin® 600 mg TABLETS (ibuprofen)

One tablet t.i.d.

Please turn page for a brief summary of prescribing information.

Upjohn The Upjohn Company
Kalamazoo, Michigan 49001



Only Ativan (lorazepam)

offers all these benefits in addition to rapid relief of anxiety:

relief of anxiety associated with depressive symptoms

clearance not significantly delayed by age, liver or kidney dysfunction

cumulative sedative effects seldom a problem

little likelihood of drug interaction

all benzodiazepines produce additive effects when taken with alcohol or other CNS depressants

no significant changes in vital signs in cardiovascular patients*

short duration of action, simple metabolism

*Benzodiazepines have not been shown to be of benefit in treating the cardiovascular component

For [illegible] information, please see following page.

[illegible] Wyeth Laboratories

Wyeth Laboratories


New studies uncover the potassium effects of beta-2 blockade
Clinical pharmacology data from The New England Journal of Medicine:
"...when normal young men are given infusions of epinephrine at levels such as those that circulate in patients with myocardial infarction, their serum potassium concentrations fall by about 0.8 [mmol] per liter. Hypokalemia is prevented by selective beta-2 blockade."[1]
Evidence that all beta blockers are not created equal.

Right from the start in hypertension...



Once-daily INDERAL LA (propranolol HCl) for smooth blood pressure control without the potassium problems of diuretics

Once-daily INDERAL LA (propranolol HCl) avoids the risk of diuretic-induced ECG abnormalities due to hypokalemia.[2,3] In addition, INDERAL LA preserves potassium balance without additive agents or supplements while providing simple, well-tolerated therapy with broad cardiovascular benefits.

Once-daily INDERAL LA for the cardiovascular benefits of the world's leading beta blocker

Simply start with 80 mg once daily. Dosage may be increased to 120 mg to 160 mg once daily as needed to achieve additional control.

Like conventional INDERAL tablets, INDERAL LA should not be used in the presence of congestive heart failure, sinus bradycardia, heart block greater than first degree, and bronchial asthma.

80 mg 120 mg 160 mg

The appearance of these capsules is a registered trademark of Ayerst Laboratories.

Please see brief summary of prescribing information on the next page for further details.

Once-daily For beta-1/beta-2 blockade INDERAL® LA (PROPRANOLOL HCl) LONG ACTING CAPSULES



The appearance of these capsules is a registered trademark of Ayerst Laboratories.

BRIEF SUMMARY *(FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE CIRCULAR.)*

INDERAL® LA brand of propranolol hydrochloride **(Long Acting Capsules)**

DESCRIPTION. Inderal LA is formulated to provide a sustained release of propranolol hydrochloride. Inderal LA is available as 80 mg, 120 mg, and 160 mg capsules.

CLINICAL PHARMACOLOGY. INDERAL is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by INDERAL, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately.

INDERAL LA Capsules (80, 120, and 160 mg) release propranolol HCl at a controlled and predictable rate. Peak blood levels following dosing with INDERAL LA occur at about 6 hours and the apparent plasma half-life is about 10 hours. When measured at steady state over a 24-hour period the areas under the propranolol plasma concentration-time curve (AUCs) for the capsules are approximately 60% to 65% of the AUCs for a comparable divided daily dose of INDERAL tablets. The lower AUCs for the capsules are due to greater hepatic metabolism of propranolol, resulting from the slower rate of absorption of propranolol. Over a twenty-four (24) hour period, blood levels are fairly constant for about twelve (12) hours then decline exponentially.

INDERAL LA should not be considered a simple mg for mg substitute for conventional propranolol and the blood levels achieved do not match (are lower than) those of two to four times daily dosing with the same dose. When changing to INDERAL LA from conventional propranolol, a possible need for retitration upwards should be considered especially to maintain effectiveness at the end of the dosing interval. In most clinical settings, however, such as hypertension or angina where there is little correlation between plasma levels and clinical effect, INDERAL LA has been therapeutically equivalent to the same mg dose of conventional INDERAL as assessed by 24-hour effects on blood pressure and on 24-hour exercise responses of heart rate, systolic pressure and rate pressure product. INDERAL LA can provide effective beta blockade for a 24-hour period.

The mechanism of the antihypertensive effect of INDERAL has not been established. Among the factors that may be involved in contributing to the antihypertensive action are (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use. Effects on plasma volume appear to be minor and somewhat variable. INDERAL has been shown to cause a small increase in serum potassium concentration when used in the treatment of hypertensive patients.

In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity.

In dosages greater than required for beta blockade, INDERAL also exerts a quinidine-like or anesthetic-like membrane action which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.

The mechanism of the antimigraine effect of propranolol has not been established. Beta-adrenergic receptors have been demonstrated in the pial vessels of the brain.

Beta receptor blockade can be useful in conditions in which, because of pathologic or functional changes, sympathetic activity is detrimental to the patient. But there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function is maintained by virtue of sympathetic drive which should be preserved. In the presence of AV block, greater than first degree, beta blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta blockade results in bronchial constriction by interfering with adrenergic bronchodilator activity which should be preserved in patients subject to bronchospasm.

Propranolol is not significantly dialyzable.

INDICATIONS AND USAGE. Hypertension: INDERAL LA is indicated in the management of hypertension; it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. INDERAL LA is not indicated in the management of hypertensive emergencies.

Angina Pectoris Due to Coronary Atherosclerosis: INDERAL LA is indicated for the long-term management of patients with angina pectoris.

Migraine: INDERAL LA is indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use.

Hypertrophic Subaortic Stenosis: INDERAL LA is useful in the management of hypertrophic subaortic stenosis, especially for treatment of exertional or other stress-induced angina, palpitations, and syncope. INDERAL LA also improves exercise performance. The effectiveness of propranolol hydrochloride in this disease appears to be due to a reduction of the elevated outflow pressure gradient which is exacerbated by beta-receptor stimulation. Clinical improvement may be temporary.

CONTRAINDICATIONS. INDERAL is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS) unless the failure is secondary to a tachyarrhythmia treatable with INDERAL.

WARNINGS. CARDIAC FAILURE: Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta blockers should be avoided in overt congestive heart failure, if necessary, they can be used with close follow-up in patients with a history of failure who are well compensated and are receiving digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or INDERAL should be discontinued (gradually, if possible).

IN PATIENTS WITH ANGINA PECTORIS, there have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of INDERAL therapy. Therefore, when discontinuance of INDERAL is planned the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If INDERAL therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute INDERAL therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)—PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS. INDERAL should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta receptors.

MAJOR SURGERY: The necessity or desirability of withdrawal of beta-blocking therapy *prior* to major surgery is controversial. It should be noted, however, that the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

INDERAL (propranolol HCl), like other beta blockers, is a competitive inhibitor of beta-receptor agonists and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Difficulty in starting and maintaining the heartbeat has also been reported with beta blockers.

DIABETES AND HYPOGLYCEMIA: Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute hypoglycemia in labile insulin-dependent diabetes. In these patients, it may be more difficult to adjust the dosage of insulin.

THYROTOXICOSIS: Beta blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol does not distort thyroid function tests.

IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME, several cases have been reported in which, after propranolol, the tachycardia was replaced by a severe bradycardia requiring a demand pacemaker. In one case this resulted after an initial dose of 5 mg propranolol.

PRECAUTIONS. *General:* Propranolol should be used with caution in patients with impaired hepatic or renal function. INDERAL (propranolol HCl) is not indicated for the treatment of hypertensive emergencies.

Beta adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that INDERAL may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

Clinical Laboratory Tests: Elevated blood urea levels in patients with severe heart disease, elevated serum transaminase, alkaline phosphatase, lactate dehydrogenase.

DRUG INTERACTIONS: Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if INDERAL is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have been conducted to evaluate toxic effects and carcinogenic potential. In 18-month studies in both rats and mice, employing doses up to 150 mg/kg/day, there was no evidence of significant drug-induced toxicity. There were no drug-related tumorigenic effects at any of the dosage levels. Reproductive studies in animals did not show any impairment of fertility that was attributable to the drug.

Pregnancy: Pregnancy Category C. INDERAL has been shown to be embryotoxic in animal studies at doses about 10 times greater than the maximum recommended human dose.

There are no adequate and well-controlled studies in pregnant women. INDERAL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: INDERAL is excreted in human milk. Caution should be exercised when INDERAL is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS. Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.

Cardiovascular: bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.

Central Nervous System: lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal: nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation; mesenteric arterial thrombosis; ischemic colitis.

Allergic: pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat; laryngospasm and respiratory distress.

Respiratory: bronchospasm.

Hematologic: agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Auto-Immune: In extremely rare instances, systemic lupus erythematosus has been reported.

Miscellaneous: alopecia, LE-like reactions, psoriasiform rashes, dry eyes, male impotence, and Peyronie's disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.

DOSAGE AND ADMINISTRATION. INDERAL LA provides propranolol hydrochloride in a sustained-release capsule for administration once daily. If patients are switched from INDERAL tablets to INDERAL LA capsules, care should be taken to assure that the desired therapeutic effect is maintained. INDERAL LA should not be considered a simple mg for mg substitute for INDERAL. INDERAL LA has different kinetics and produces lower blood levels. Retitration may be necessary especially to maintain effectiveness at the end of the 24-hour dosing interval.

HYPERTENSION—*Dosage must be individualized.* The usual initial dosage is 80 mg INDERAL LA once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.

ANGINA PECTORIS—*Dosage must be individualized.* Starting with 80 mg INDERAL LA once daily, dosage should be gradually increased at three to seven day intervals until optimum response is obtained. Although individual patients may respond at any dosage level, the average optimum dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.

If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks (see WARNINGS).

MIGRAINE—*Dosage must be individualized.* The initial oral dose is 80 mg INDERAL LA once daily. The usual effective dose range is 160-240 mg once daily. The dosage may be increased gradually to achieve optimum migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximum dose, INDERAL LA therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.

HYPERTROPHIC SUBAORTIC STENOSIS—80-160 mg INDERAL LA once daily.

PEDIATRIC DOSAGE—At this time the data on the use of the drug in this age group are too limited to permit adequate directions for use.

REFERENCES

1. Epstein FH, Rosa RM: Adrenergic control of serum potassium. *N Engl J Med* 1983; 309:1450-1451. **2.** Holland OB, Nixon JV, Kuhnert L: Diuretic-induced ventricular ectopic activity. *Am J Med* 1981;70:762-768. **3.** Holme I, Helgeland A, Hjermann I, et al: Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo study and in MRFIT. *JAMA* 1984;251:1298-1299.

9411/1184

Ayerst® AYERST LABORATORIES
New York, N.Y. 10017


In 7 of 10
anxious
geriatrics...
Anxiety and
depressive
symptoms
go hand
in hand.

Xanax rapidly relieves anxiety with depressive symptoms.



In a recent clinical study[1] of 83 geriatric patients with clinical anxiety, 73% were diagnosed as having symptoms of depressed mood.

XANAX is well suited for therapy because it demonstrates greater efficacy than placebo in reducing the Hamilton Anxiety Rating Scale Total Score and individual items including depressed mood (see Figure).

With clinical advantages for geriatric patients.

- **Rapidly relieves** the symptoms of anxiety
- **Rapidly relieves** associated depressed mood
- **Well tolerated**—mild, transient drowsiness, the most commonly reported side effect the first week of therapy, shows a marked decrease thereafter and is not significantly different from that of placebo
- **Does not cause** cardiotoxicity
- **Specific geriatric dosage**—0.25 mg, two or three times daily

1. Cohn JB: Double-blind safety and efficacy comparison of alprazolam and placebo in the treatment of anxiety in geriatric patients. *Curr Ther Res* 1984;35(1):100-112.



Xanax® 0.25 mg Tablets
alprazolam C-IV

Upjohn THE UPJOHN COMPANY
Kalamazoo, Michigan 49001 USA

Please see next page for brief summary of prescribing information.

Kodak presents...



New KODAK EKTACHEM DT60 Analyzer

A timely invest

The KODAK EKTACHEM DT60 Analyzer creates an extra service for your patients without extra investment in labor. And because it can pay for itself in three months, it's a timely investment in your future.

The chemistry tests you need

With the DT60 Analyzer you perform key chemistry tests in your own office instead of using an outside laboratory. Available tests include glucose, cholesterol, triglycerides, BUN, uric acid, sodium, and potassium, with total hemoglobin and bilirubin coming soon.

The time you need

Get test results in five minutes or less; perform up to 75 tests an hour. Save time waiting for results to assist in your diagnosis, and on follow-up phone calls.

The accuracy you need

The DT60 Analyzer uses proven technology and methodology from the KODAK EKTACHEM 400 and 700 Analyzers, which

ment for your office.



provide millions of accurate, precise results to clinical laboratories nationwide.

The simplicity you need

The DT60 Analyzer, compact as a personal computer, features dry slide technology to eliminate wet reagents. It is automated to free up your staff, and training takes only minutes. From the finger-stick sample to results printout, the DT60 Analyzer is simplicity itself.

To see what the DT60 Analyzer can do for you, write Eastman Kodak Company, Dept. 740-B, 343 State Street, Rochester, NY 14650, or call **1 800 44KODAK,** Ext 423 (1 800 445-6325, Ext 423) today.

Kodak

Leading the way in healthcare technology for over 100 years.

KODAK EKTACHEM Clinical Chemistry Products

In Hypertensives Over 50, Diuretics Are Preferred

The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diuretics as the favored monotherapy in patients over 50 years of age, regardless of sex or race.

Beta Blockers Aren't for Everyone...

For Hypertensive Patients*Over 50

P R E S C R I B E®

25 mg Hydrochlorothiazide/**50 mg** Triamterene/SKF

Used with Confidence for over 19 Years

Serum K^+ and BUN should be checked periodically (see Warnings and Precautions).

Before prescribing, see complete prescribing information in SK&F CO. literature or *PDR*. The following is a brief summary.

* **WARNING**

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. **Associated widened QRS complex or arrhythmia requires prompt additional therapy.** Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: The bioavailability of the hydrochlorothiazide component of 'Dyazide' is about 50% of the bioavailability of the single entity. Theoretically, a patient transferred from the single entities of Dyrenium (triamterene, SK&F CO.) and hydrochlorothiazide may show an increase in blood pressure or fluid retention. Similarly, it is also possible that the lesser hydrochlorothiazide bioavailability could lead to increased serum potassium levels. However, extensive clinical experience with 'Dyazide' suggests that these conditions have not been commonly observed in clinical practice. Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a red and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

BRS-DZ:L39

The unique red and white Dyazide® capsule: Your assurance of SK&F quality.

a product of

SK&F CO.

Carolina, PR 00630

The Evidence Continues To Accumulate. Low-Dose Toxic Exposure to Common Organic Chemical Compounds is Implicated in an Ever-Broadening Range of Clinical Illnesses, Including:

- hepatitis
- lung disease
- anemia
- neurologic disorders
- cancer
- reproductive damage
- renal dysfunction
- immuno-suppression
- dermatitis

But there has been no array of accurate, reliable, rapid and cost-effective office procedures to screen for such exposures. Until now.

Advisory to Clinicians:

Enviro•Health Systems, Inc. today offers physicians and certain clinical laboratories in the U.S., Canada, Europe and Australia three specific *quantitative* procedures addressing that need:

GVST,™ a general volatile organics test screening for 13 specific aromatic and halogenated toxic compounds at low (parts-per-billion) levels.

CPhST,™ a chlorinated phenols screening procedure for the extensively used chlorophenol family of compounds.

CPST,™ a pesticide test detecting 19 common organochlorine pesticides at the same trace levels from a single serum specimen.

We supply **GVST,™ CPhST™** and **CPST™** test kits to physicians at cost upon request. Each kit contains all necessary pre-tested glassware, needles and syringes, together with full instructions and return mailers. Enviro•Health Systems' labs in Richardson, Texas process serum samples and report results within 48 hours of receipt. Each analysis costs $125 or less.

Throughout 1985, we intend to accelerate Enviro•Health's R & D programs to meet clinical demand for similar inexpensive, office-administered Dx and Rx screening tests for volatile brominated organics, glycol ethers, herbicides and aniline-related compounds.

Now, as never before, the practice of medicine rewards the efficient and the cost conscious. The **GVST,™ CPhST™** and **CPST™** offer the alert physician of today three new, ready and valuable additions to the practitioner's armamentarium. And an ethical clinical advantage.

An edge.

Contact us for details.

Enviro-Health Systems, Inc.
3660 Gentilly Boulevard
New Orleans, LA 70122

Phone: 504/943-4427

To: Enviro•Health Systems, Inc.

From:

Name

Organization

Street Address

City State Zip

Please send information on:

- ☐ GVST™
- ☐ CPhST™
- ☐ CPST™
- ☐ Information on all 3 tests.

Also:

- ☐ Send me future mailings.
- ☐ Send complimentary starter kit for _____ ST™



More people have survived cancer than now live in the City of Los Angeles.

We are winning.

Please support the AMERICAN CANCER SOCIETY®

Increase your level of reimbursement with AHM's vital seminar:

Insurance Coding: Procedural CPT-85 and Diagnostic ICD-9-CM"

A one-day professional workshop designed to increase the proficiency of your staff in collecting what's due you. The latest revisions on specific California regulations.

Here are just a few of the techniques your staff will learn:

1. Why correct coding increases your level of reimbursement — now and in the future. 2. How the insurance carriers use coding. 3. How to recognize and code each procedural component. 4. Understanding relationships of diagnoses and procedures. 5. Step-by-step through the ICD-9-CM — where to begin. 6. How to avoid the "no-pay" and "desperation" codes.

• How coding will input into fee profiles of the future. • Who codes the procedures and diagnoses that you don't! • How the insurance carriers use codes to lower your reimbursement. • Recognition of the diagnosis from the hospital chart or office record. • Use of simplified terminology to relate procedures as they appear "on your records" to the CPT-85. • Defining levels of service for higher reimbursement. • Your patient's chart — how to organize it for ease of coding and office efficiency. • Keys to unlock the complexity of the ICD-9-CM.

Any or all of the following staff members will benefit from our seminar: Insurance Secretary, Receptionist, Patient Interviewer, Credit & Collections Counselor, Bookkeeper, Assistants, New Staff Members, Office Manager, Supervisors, Coordinators, and Doctors.

California Seminar Schedule

Fresno	**Apr. 1, 1985**	**Fresno Hilton • 1055 Van Ness**
Orange County	**Apr. 2, 1985**	**Westin South Coast Plaza • 666 Anton Blvd.**
Marina Del Rey	**Apr. 3, 1985**	**Marina Internat'l Hotel • 4200 Admiralty Way**
Pasadena	**Apr. 4, 1985**	**Holiday Inn • 303 E. Cordova St.**
Anaheim	**Apr. 5, 1985**	**Hilton at the Park • 1855 S. Harbor Blvd.**
Sacramento	**Apr. 15, 1985**	**Sacramento Inn • 1401 Arden Way**
Thousand Oaks	**Apr. 15, 1985**	**Howard Johnsons • 75 W. Thousand Oaks Blvd.**
Palo Alto	**Apr. 16, 1985**	**Hyatt Rickeys • 4219 El Camino**
Torrance	**Apr. 16, 1985**	**Torrance Marriott • 3635 Fashion Way**
San Francisco	**Apr. 17, 1985**	**Sheraton Palace Hotel • 639 Market St.**
Los Angeles	**Apr. 17, 1985**	**Hyatt on Sunset • 8401 Sunset Blvd.**
Seattle, WA	**Apr. 18, 1985**	**Hyatt Seattle • 17001 Pacific Hwy. South**
Pasadena	**Apr. 18, 1985**	**The Pasadena Hilton • 150 S. Los Robles at Cordova St.**
Portland, OR	**Apr. 19, 1985**	**Westin Benson • SW Broadway at Oak St.**
Anaheim	**Apr. 19, 1985**	**Hilton at the Park • 1855 S. Harbor Blvd.**

Seminars start at 9 a.m. and are over at 4:30 p.m. each date



All seminars are taught by our highly qualified AHM staff members, backed by our company's 22 years experience of counseling in almost all facets of the health care industry. Tuition includes a comprehensive work-book/reference manual, sample forms and resource material plus refreshments. Seminar is tax deductible and is fully guaranteed or your tuition will be refunded if you are not completely satisfied. Over 38,700 physicians and their support staff have attended AHM seminars nationwide.

Fee: $135.00 each for one attendee from your practice.
$115.00 each for two or more attendees from your practice.

Attendance is limited...please register early!

Register: Call Toll Free 800-543-4332

ADMINISTRATIVE HEALTH MANAGEMENT GROUP, INC.
2600 Far Hills Avenue • Dayton, Ohio 45419

"When the Ayerst rep told me it costs about 45¢ a day, I said you can stop right there."

Most doctors are pleasantly surprised to learn that the average cost of daily therapy with the world's most widely used beta blocker is so little, not much more than the cost of a daily newspaper.

When it's INDERAL (propranolol hydrochloride) tablets you want for your hypertension patients, remember to specify Dispense As Written (DAW) or Do Not Substitute on your prescriptions. That way, you can always be assured they'll get INDERAL®. Please see next page for brief summary of prescribing information.

INDERAL®
(PROPRANOLOL HCl)
Small price to pay.

"When the Ayerst rep told me it costs about 45¢ a day, I said you can stop right there."

INDERAL® TABLETS
(PROPRANOLOL HCl)





BRIEF SUMMARY (FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE CIRCULAR.)

INDERAL® (propranolol hydrochloride) Tablets

CONTRAINDICATIONS

INDERAL is contraindicated in 1) cardiogenic shock, 2) sinus bradycardia and greater than first degree block, 3) bronchial asthma, 4) congestive heart failure (see WARNINGS) unless the failure is secondary to a tachyarrhythmia treatable with INDERAL.

WARNINGS

CARDIAC FAILURE: Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta blockers should be avoided in overt congestive heart failure, if necessary they can be used with close follow-up in patients with a history of failure who are well compensated and are receiving digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or INDERAL should be discontinued (gradually, if possible).

IN PATIENTS WITH ANGINA PECTORIS, there have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of INDERAL therapy. Therefore, when discontinuance of INDERAL is planned the dosage should be gradually reduced over at least a few weeks and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If INDERAL therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute INDERAL therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)-- PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA BLOCKERS. INDERAL should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta receptors.

MAJOR SURGERY: The necessity or desirability of withdrawal of beta-blocking therapy prior to major surgery is controversial. It should be noted, however, that the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

INDERAL, like other beta blockers, is a competitive inhibitor of beta-receptor agonists and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Difficulty in starting and maintaining the heartbeat has also been reported with beta blockers.

DIABETES AND HYPOGLYCEMIA: Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute hypoglycemia in labile insulin-dependent diabetes. In these patients, it may be more difficult to adjust the dosage of insulin.

THYROTOXICOSIS: Beta blockade may mask certain clinical signs of hyperthyroidism. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. Propranolol does not distort thyroid function tests.

IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME, several cases have been reported in which, after propranolol, the tachycardia was replaced by a severe bradycardia requiring a demand pacemaker. In one case this resulted after an initial dose of 5 mg propranolol.

PRECAUTIONS

General: Propranolol should be used with caution in patients with impaired hepatic or renal function. INDERAL is not indicated for the treatment of hypertensive emergencies.

Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that INDERAL (propranolol hydrochloride) may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

Clinical Laboratory Tests: Elevated blood urea levels in patients with severe heart disease, elevated serum transaminase, alkaline phosphatase, lactate dehydrogenase.

DRUG INTERACTIONS: Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if INDERAL is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have been conducted to evaluate toxic effects and carcinogenic potential. In 18-month studies in both rats and mice, employing doses up to 150 mg/kg/day, there was no evidence of significant drug-induced toxicity. There were no drug-related tumorigenic effects at any of the dosage levels. Reproductive studies in animals did not show any impairment of fertility that was attributable to the drug.

Pregnancy: Pregnancy Category C. INDERAL has been shown to be embryotoxic in animal studies at doses about 10 times greater than the maximum recommended human dose.

There are no adequate and well-controlled studies in pregnant women. INDERAL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: INDERAL is excreted in human milk. Caution should be exercised when INDERAL is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.

Cardiovascular: bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.

Central Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal: nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.

Allergic: pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm and respiratory distress.

Respiratory: bronchospasm.

Hematologic: agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.

Auto-Immune: In extremely rare instances, systemic lupus erythematosus has been reported.

Miscellaneous: alopecia, LE-like reactions, psoriasiform rashes, dry eyes, male impotence, and Peyronie's disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae reported for a beta blocker (practolol) have not been associated with propranolol.

*The appearance of INDERAL tablets is a registered trademark of Ayerst Laboratories.

9418/185

Ayerst® AYERST LABORATORIES
New York, N.Y. 10017

MOST MALPRACTICE LAWSUITS ARE SURPRISES.

(EXCEPT TO CLAIMS EXPERTS)

The experts who handle claims every day have learned that —

1. Most are caused by simple things
2. Most could be avoided

Listen to the experts, dial SCPIE-on-Call, 1-800-821-3887 (Request tape by number)

Get the latest word on the pitfalls of practice via tape-recorded messages —

Tape No. 1	Why Good Doctors Lose Cases
Tape No. 2	Informed Consent: New Problems
Tape No. 3	Why Patients are Unhappy and Sue
Tape No. 4	Early Warning to Avoid Losses
Tape No. 5	Laboratory Report Follow-Up
Tape No. 6	Requests for Copies of Records – Take Care

Available 9 a.m. to 8 p.m. Monday–Friday, 10 a.m. to 6 p.m. Saturday

Tapes run about 3 to 4 minutes. It's time well spent. It could help avoid an unpleasant surprise. It's a free service sponsored by

Southern California
Physicians Insurance Exchange
2029 Century Park East
Suite 2300
Los Angeles, CA 90067

Easy To Take



Keflex®
cephalexin

Additional information available to the profession on request.

DISTA

420113

Dista Products Company
Division of Eli Lilly and Company
Indianapolis, Indiana 46285
Mfd. by Eli Lilly Industries, Inc.
Carolina, Puerto Rico 00630

Classified Advertisements

The rate for each insertion is **$5 per line** (average six words per line) **with five line ($25) minimum.** Box number charge: $5 each month.

Classified display rates $50 per inch.

Copy for classified advertisements should be received not later than **the first of the month preceding issue. All copy must be typed or printed.** • Classified advertisers using Box Numbers forbid the disclosure of their identity. Your inquiries in writing will be forwarded to Box Number advertisers. The right is reserved to reject or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

THE WESTERN JOURNAL OF MEDICINE
44 GOUGH STREET, SAN FRANCISCO, CA 94103

PHYSICIANS WANTED

NEPHROLOGIST—Board certified or eligible, to join a 150 physician multispecialty prepaid medical group in Hawaii. Stimulating practice, university-affiliated teaching program, excellent fringe benefits. Write: Hawaii Permanente Medical Group, Inc., 1697 Ala Moana Blvd,. Honolulu, Hawaii 96815. An Equal Opportunity Employer.

PSYCHIATRISTS—Eighty bed private, free standing psychiatric hospital requires one adult and one child/adolescent psychiatrist willing to relocate to Anchorage, AK. Hospital will pay relocation and overhead expenses and provide an income guarantee. Current inpatient experience and a genuine interest in inpatient therapy is required. Send CV to Administrator, Charter North Hospital, PO Box 8-9019, Anchorage, AK 99508.

PSYCHIATRIST—Eighty bed private, free standing hospital requires a Medical Director for the chemical dependency treatment program. Requires experienced psychiatrist strongly interested in the treatment of chemically dependent adults and adolescents in an AA oriented program. Position requires a combination of private practice and medico-administrative duties. There is a six figure income guarantee with payment of relocation and overhead expenses. Position available immediately. Send CV to Administrator, Charter North Hospital, PO Box 8-9019, Anchorage, AK 99508.

FAMILY PRACTITIONER BC/BE needed for large multi-specialty clinic in **San Francisco** Bay area. Competitive salary first year, with excellent benefits. Eligible for full partnership after one year. Send resume to Administrator, San Jose Medical Group, 45 South 17th St., San Jose, CA 95112.

WANTED: UNIVERSITY TRAINED GENERAL SURGEON to join three other general surgeons in 14-physician clinic. Location: southern Idaho. Surrounding area abounds in recreational opportunities. Applicant must have excellent qualifications. Send resume to Box 1233, Twin Falls, ID 83301.

UROLOGIST—Board eligible/certified Urologist needed for busy surgical practice. individual should have both adult and pediatric experience. For information, call Donald B. Dawson, Director of Physician Staffing, toll-free at 1 (800) 446-2255, in California call 1 (800) 336-2255. For opportunities in Utah call Maryalys Poulson collect at (801) 355-1234. FHP Professional Staffing, 400 Oceangate Blvd., Suite 1317, Long Beach, CA 90802.

Physicians

The Perfect Practice Is One That Lets You Practice

At Westworld Community Healthcare, Inc., physicians have something very special: **Time.** Time to devote to their practices, and to their patients. And they have the time because we handle all the business details their practices demand.

The goal of every Westworld Hospital is to help our physicians be as productive as they can possibly be. We handle all the paperwork and administrative details, and assist in everything from setting up medical offices to providing staffing and equipment. What's more, we provide an excellent compensation package - competitive with private practice - along with incentive for additional income. And since our commitment is to meet the unique health care needs of rural America, there is no competing with hundreds of other practitioners for patients.

All of these advantages mean **security** for the Westworld physician. If your commitment is to the highest standards in patient care, and if a rural environment sounds inviting to you, investigate Westworld Community Healthcare. We have a variety of attractive practice opportunities in rural America. Call collect now for more information, or send your curriculum vitae to: **Mr. Joel Feinstein, Dept. PH-3, (714) 768-2981, Westworld Community Healthcare, Inc., 23072 Lake Center Drive, #200, Lake Forest, CA 92630-2880.** We are an equal opportunity employer m/f.

Westworld Community Healthcare, Inc.

A Caring Company Needing A Few Caring People!

WORK PART TIME: Position available for Internist or GP with Internal Medicine experience to work at Primary Care Practice in Northern California Sierra foothills community of 25,000, 20 miles from Chico. Share rotating practice with two other MDs; you work one week in three. Out-patient and in-patient responsibilities in modern, fully-equipped hospital. Minimum salary of $1,800/week, plus incentives. Insurance and housing provided. Send CV and references to: David Lomba, Manager, 133 'A' Ascot Ct., Moraga, CA 94556.

WASHINGTON, EMERGENCY PHYSICIAN: Immediate opening for board qualified physician in new community hospital in Olympia. Long established local physician group. Guaranteed minimum. Send CV to Mark Urmanski, MD, PO Box 2786, Olympia, WA 98507 or call Ray Brasher at (206) 456-7289

GENERAL/FAMILY PRACTITIONERS. If you are looking for an opportunity to be in the forefront of medical care, practice preventive medicine, work with other innovative professionals, and earn a comfortable living in pleasant surroundings, send your curriculum vitae to Physician Placement Dept-49. An equal opportunity employer. CIGNA Healthplans of California, 700 N. Brand Blvd., Suite 500, Glendale, CA 91203.

ASSOCIATE IN PEDIATRICS: Kern Medical Center, Bakersfield, California, a Southern California teaching hospital affiliated with UCLA School of Medicine, seeks an Associate in its Department of Pediatrics. Prerequisites include eligibility or certification by the American Board of Pediatrics, strong interest in teaching and qualifications for faculty appointment in the UCLA Department of Pediatrics. Compensation and benefits are competitive. Please reply with curriculum vitae to Jess Diamond, MD, Chairman, Kern Medical Center Department of Pediatrics, 1830 Flower St., Bakersfield, CA 93305, or telephone (collect) at (805) 326-2263.

WANTED: Physician to staff Department of Initial Care of the Wenatchee Valley Clinic. Salary of $50,000/year for 40-48 hours/week, plus Benefit Package includes malpractice insurance, vacation, meeting time, etc. Ideal family, outdoor recreation area. Address inquiries to: Initial Care, Wenatchee Valley Clinic, 820 North Chelan, Wenatchee, WA 98801; (509) 663-8711.

GENERAL INTERNIST, BOARD CERTIFIED/ ELIGIBLE: Multi-specialty group, university town central Washington, has space and services available on a lease or compensation basis with future partnership if desired. Contact A. J. Grose, MD, Medical Building Associates, PO Box 369, Ellensburg, WA 98926.

HAYWARD, CALIFORNIA. 20-man Bay Area multispecialty group with four pediatricians seeking Board certified or eligible Pediatrician to replace retiring physician, May 1985. Group active in HMOs and satellite office. Contact: Donald L. Lass, Administrator, Hayward Medical Group, 27212 Calaroga Ave., Hayward, CA 94545; (415) 785-5000.

PUGET SOUND/WASHINGTON—Interested in establishing practice in area of excellent recreational opporutnities and quality lifestyle? The following BC/BE positions are available in multispecialty clinic of 21 physicians: Occupational Medicine, Ob-Gyn, ENT, Gastroenterology Surgery, Orthopedics, and Urology. Excellent compensation and benefits. Send CV's to: Executive Director, Western Clinic, PO Box 5467, Tacoma, WA 98405.

OB/GYN—BOARD ELIGIBLE CERTIFIED. For provision of gynecological services and obstetrical consultations to population of 15,000. Established medical community includes family practitioners as well as several specialists. Acute care provided by a well-equipped, 34 bed hospital located in an alpine area. Enjoy the benefits of living year 'round in a vacationer's paradise. Contact Larry Price, MD, PO Box 1049, Quincy, CA 95971.

INTERNIST—Board eligible/certified Internist needed. Full range of in hospital and out-patient work responsibilities. For information, call Donald B. Dawson, Director of Physician Staffing, toll-free at 1 (800) 446-2255, in California call 1 (800) 336-2255. For opportunities in Utah call Maryalys Poulson collect at (801) 355-1234. FHP Professional Staffing, 400 Oceangate Blvd., Suite 1317, Long Beach, CA 90802.

(Continued on Page 438)

THE PROFESSIONALS IN PROFESSIONAL LIABILITY INSURANCE. THE DOCTORS' COMPANY.

THE PROFESSIONALS FOR THE MEDICAL PROFESSION. THE DOCTORS' LIFE INSURANCE COMPANY.



THE DOCTORS' COMPANY
AN INTERINSURANCE EXCHANGE
THE DOCTORS'
LIFE INSURANCE COMPANY
A WHOLLY-OWNED SUBSIDIARY OF THE DOCTORS' COMPANY

401 WILSHIRE BLVD., SANTA MONICA, CA 90401
(213) 451-3011
TOLL FREE, (800) 352-7271 (CALIFORNIA);
(800) 421-2368 (OTHER STATES)

SERVING THE INSURANCE NEEDS OF
PHYSICIANS IN CALIFORNIA/NEVADA/
WYOMING/MONTANA

(Continued from Page 436)

PHYSICIANS WANTED

FAMILY PRACTITIONER—Out patient care. Full-time position available for residency trained, Board eligible/certified Family Practitioner interested in a position involving out-patient care. Pediatrics, Pre-Natal Care, Adult medicine, Orthopedics and minor surgery responsibilities are available. For information, call Donald B. Dawson, Director of Physician Staffing, toll-free at 1 (800) 446-2255, in California call 1 (800) 336-2255. For opportunities in Utah call Maryalys Poulson collect at (801) 355-1234. FHP Professional Staffing, 400 Oceangate Blvd., Suite 1317, Long Beach, CA 90802.

FHP is seeking an Orthopedic Surgeon who has completed or is currently involved in a total arthroplasty fellowship, or an orthopedic surgeon with extensive experience in total joint replacement with particular reference to revision arthroplasty. For information, call Donald B. Dawson, Director of Physician Staffing, toll-free at 1 (800) 446-2255, in California call 1 (800) 336-2255. For opportunities in Utah call Maryalys Poulson collect at (801) 355-1234. FHP Professional Staffing, 400 Oceangate Blvd., Suite 1317, Long Beach, CA 90802.

SEATTLE AREA INTERNIST. Established individual practice of medicine will become available in the next 6-12 months. Suburban community with rapidly expanding services and recently constructed hospital addition. Office space in multispecialty building. For additional information write to E. R. Larson, MD, PO Box 238, Seahurst, WA 98062.

ASSISTANT/ASSOCIATE PROFESSOR. Full-time faculty position available in the Department of Family Practice, University of California, Davis; level of appointment commensurate with academic experience and credentials. Should be Board certified by the American Board of Family Practice with interest, training, and/or experience in teaching, research and academic publication activities. The position will remain open until filled . . . applications will not be accepted after 5/31/85. Send CV to Robert C. Davidson, MD, Chair, Department of Family Practice, University of California, Davis, 2221 Stockton Blvd., Sacramento, CA 95817. The University of California is an affirmative action, equal opportunity employer.

WESTERN US, OPENINGS—Several multi-specialty groups and clinics have asked us to recruit for over 100 positions of various specialties, Western States Physician Search, 240 W Shaw, Suite C, Clovis, CA 93612; (209) 297-7748.

FAMILY PHYSICIAN BC/BE to join four Family Physicians in San Francisco area. Partnership opportunity. Contact: Tamara Cheney, MD, 2190 Peralta Blvd., Fremont, CA 94536; (415) 793-2645.

BE/BC INTERNIST needed to associate with busy Internist in Wyoming. Growing community, excellent schools, new hospital, and great skiing and recreational opportunities nearby. Available now or summer, 1985. Send CV to Box 6461, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

GASTROENTEROLOGIST: BC or BE, to associate with four man Internal Medicine group in small Northern California city. Modern, complete, endoscopy lab at local hospital. Salary plus percentage. Early partnership. Please reply Box 6459, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

INTERMEDIATE CARE FACILITY for developmentally disabled seeks a full-time general practitioner or pediatrician. Competitive salary, paid vacations, sick leave, medical insurance and retirement benefits plus educational opportunities. Send curriculum vitae to R. Ruvalcaba, MD, Clinical Director, Rainier School, Box 600, Buckley, WA 98321.

CARDIOLOGIST—Board eligible/certified Cardiologist needed. Should be proficient in catheterization and implantation of permanent and temporary pacemakers. Both invasive and non-invasive experience preferred. For information, call Donald B. Dawson, Director of Physician Staffing, toll-free at 1 (800) 446-2255, in California call 1 (800) 336-2255. For opportunities in Utah call Maryalys Poulson collect at (801) 355-1234. FHP Professional Staffing, 400 Oceangate Blvd., Suite 1317, Long Beach, CA 90802.

FAMILY PHYSICIAN AND OB/GYN CONSULTANT for growing Primary Care health Center in South Bay Area. Must be Board certified or eligible. Spanish speaking preferred. Send CV to Gardner Community Health Center, 325 Willow Street, San Jose, CA 95110 or call Norma at (408) 998-2264. EOE M/F/H.

PHYSICIAN WANTED: Internist and FP Physician for small group practice in northern Idaho. Excellent outdoor recreational area. Write to Box 6462, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

CLINICAS DEL CAMINO REAL, INC. is seeking two Family Practice Physicians to augment its medical practice. Pay range is $4,200 to $4,800 per month, plus share of inpatient work. Fringe benefits include, three weeks vacation, sick leave, tax deferred annuity plan, twelve holidays and an excellent working environment located in Ventura County. Send résumé to: Robert S. Juarez, Executive Director, PO Box 4878, Ventura, CA 93004. Knowledge of Spanish desirable. An EOE.

FAMILY PRACTITIONER—Tulare County, California. Board certified/eligible Family Practitioner to practice in an outpatient clinic, which includes inpatient duties, with 13 physicians. Consider a semi-rural lifestyle with cultural amenities of metropolitan areas easily accessed and the Sierra Nevada Mountains nearby. Salary: $81,236-$85,376 annually. The County provides a benefit package which includes malpractice insurance coverage. Send CV to: Tulare County Personnel, Courthouse, Room 106, Visalia, CA 93291; (209) 733-6266. An Affirmative Action Employer.

INTERNIST BC/BE to join solo Internist in primary care/consultative/critical care practice. Eventual partnership. Palmdale-Lancaster, California. Submit CV, please reply Box 6460, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

OB/GYN-WASHINGTON. Expanding physician owned clinic in Edmonds, WA with one OB/GYN and three FP has opening for full- or part-time OB/GYN. We are a progressive clinic with two female physicians on our staff currently. Benefits include health, dental, disability, and life insurance. Send CV to Philip DuBois, MD, 7935 216th St. S.W. Suite E, Edmonds, WA 98020; (206) 775-0681.

FEMALE FAMILY PRACTITIONER wants partner. Rural, California coastal town. Friendly, relaxed community. Must enjoy OB/GYN and PEDS and be open to alternatives. BOX 819, Mendocino, CA 95460; (707) 937-4272.

WASHINGTON COASTAL COMMUNITY serving a population of 65,000 is actively recruiting the following specialists: ENT, Emergency Physician and a Urologist and Orthopaedic Surgeon. A variety of practice support options are available, i.e. office space, relocation assistance, etc. Enjoy the support of major West Coast Catholic Hospital System. Community has close proximity to major recreational areas and easy access to Seattle and Portland. For information send CV and references to: Nancy Friedrich, The Friedrich Group, 9284 Ferncliff N.E., Bainbridge Island, WA 98110.

GERIATRICIAN/INTERNIST to join full-time faculty of 65 in 500-bed acute care teaching hospital located in beautiful Santa Clara Valley, affiliated with Stanford University School of Medicine. Responsibilities include development and participation in comprehensive geriatric program. Salary and university appointment based on training and experience. IM Certification Required. We are an equal opportunity, affirmative action employer. Please address inquiries to Gary Steinke, MD, Director of Geriatric Program, 751 South Bascom Ave., San Jose, CA 95128.

MODEL PRIMARY CARE GROUP PRACTICE. Two Family Physicians to join small group in which each clinician devotes part time to clinical practice and the remainder of professional time to education, research or other related health service activities. Send CV and letter describing professional interest to: J.D.S Consultants, Inc., 1974 N. Gateway Blvd., Suite 102, Fresno, CA 93727.

EXECUTIVE DIRECTOR, Outpatient Surgery Center—Practicing anesthesiologist with three to five years of experience in outpatient surgery center, preferably with management responsibilities, for expanded program in new facility located in San Francisco Bay Area. Provides excellent opportunity for motivated individual. Please submit résumé to Box 6464, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

ACADEMIC NEUROLOGISTS, General Internists, Cardiologist—wanted for full-time faculty positions. Must be Board admissible or certified, interested in teaching medical students and house staff. Good balance between clinical practice and teaching with research oppoutunities available. Assistant Professor level with excellent guaranteed salary and benefits. Send CV to Victor H. Kaylarian, DO, Department of Medicine, University of Osteopathic Medicine and Health Sciences, 3200 Grand Avenue, Des Moines, IA 50312. All inquiries confidential.

PHYSICIANS WANTED

ACADEMIC GENERAL INTERNISTS, Cardiologist and Endocrinologist, DO—Wanted for full-time faculty positions. Must be Board admissible or certified, interested in teaching medical students and house staff. Good balance between clinical practice and teaching with research opportunities available. Assistant Professor level with excellent guaranteed salary and benefits. Send CV to Victor H. Kaylarian, DO, Department of Medicine, University of Osetopathic Medicine and Health Sciences, 3200 Grand Avenue, Des Moines, IA 50312. All inquiries confidential.

PEDIATRICIAN—Excellent opportunity for a Board certified/eligible Pediatrician to join two established Pediatricians in San Diego. Must replace present associate who is relocating with her husband. Close affiliation with Children's Hospital and level II community hospital nursery. Send CV to Clairemont Pediatric Medical Group, Inc., 4690 Genesee Ave., San Diego, CA 92117.

GENERAL SURGEONS needed for long-term practice opportunity in western Washington community within 2 hours of Seattle-Tacoma. Training and experience in Vascular or Pediatric Surgery desirable. Practice support package possible. Send CV and references to Nancy Friedrich, The Friedrich Group, 9284 Ferncliff N.E., Bainbridge Island, WA 98110.

FAMILY PRACTICE PHYSICIAN—for employment in Community Health Center serving rural hispanic population in Northern New Mexico. Practice includes OB, hospital service, and supervision of two PAs. Scenic mountainous area with easy access to campgrounds and ski slopes. Spanish fluency desirable; excellent benefits package. Contact John Glass at (505) 982-5565, or write to Presybterian Medical Services, PO Box 2267, Santa Fe, New Mexico 87504.

OREGON COAST—Dynamic four-physician group seeks Board certified Internist. New clinic adjacent to hospital with sophisticated ICU. Beautiful coastal community. Phone (503) 738-9551 or (503) 738-7405. Ask for Dr Wolfe.

PHYSICIAN OPENING—Ambulatory Care/Minor Emergency Center. Full/part-time for FP/IM/EM trained/experienced physician. Located in Tacoma area. Flexible scheduling, pleasant setting, quality medicine. Contact David R. Kennel, MD at 5900-100th St. S.W. Suite 31, Tacoma, WA 98499; (206) 584-3023 or 582-2542.

DIRECTOR OF FAMILY PRACTICE: 233-bed teaching hospital with residencies in Family Practice, General Surgery, Internal Medicine, and OBS/GYN is seeking a Director of Family Practice. Position available April 1985. Responsible for administration and supervision of patient care and family practice training program. Candidates should be Board-certified in Family Practice and have significant experience in administrative and teaching responsibilities. Experience in a training program preferred. Salary negotiable depending on background and experience. For additional information, submit CV and references or contact J. D. Kortzeborn, MD, Medical Director, San Joaquin General Hospital, PO Box 1020, Stockton, CA 95201; (209) 982-1800, Ext. 3052. Affirmative action/equal opportunity employer.

ANTERIOR SEGMENT FELLOWSHIP in busy private practice associated with Medical College. Intraocular Lens Implantation, including posterior chamber and anterior chamber lenses. Extracapsular and Phacoemulsification techniques. Argon and Yag Laser. Excellent benefits plus fringes. Send CV and career objectives to: Box 6450, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

SAN FRANCISCO—One-year Fellowship in Consultation/Liaison Psychiatry and Psychosomatic Medicine offered by St. Mary's Medical Center, a 550 bed private teaching hospital. Supervised clinical, teaching, and administrative experience in Psych and Med clinics, med/surg wards, Sleep Disorders Center, and unique Med-Psych Inpt Unit. Board eligibility in Psychiatry or Medicine required. Contact: D. Nevins, MD, St. Mary's Medical Center, 450 Stanyan St., San Francisco, CA 94117; (415) 750-5588.

BE/BC INTERNIST to join two Internists in private practice, NE Wyoming. Excellent call schedule. Low taxes. Located close to outdoor recreation (hunting, fishing, skiing, hiking, etc.). Guarantee salary plus bonus. Community 20,000 with referral base 35,000. Excellent schools. Superb opportunity for physician interested in private practice and eventually becoming partner. Please reply to Box 6465, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

SAN FRANCISCO EXCELSIOR AREA. Expanding family practice in underserved area has office space available for lease. Prefer complementary specialist, not mandatory. Rates, days negotiable. Limited partnership option. Spanish, Tagalog, Italian useful. Call Ms Ramirez (415) 334-7700.

PACIFIC NORTHWEST: CHEC Medical Centers will add four new ambulatory care centers to its Seattle area network during July/August. Primary care physicians interested in practice building with strong management support, regular hours, guaranteed base plus profit sharing and stock options are invited to respond. Please send CV to Richard Miller, Director of Physician Services, CHEC Medical Centers, 2200 Sixth Avenue, Suite 1200-BB, Seattle, WA 98121 or call collect (206) 728-6888.

MEDICAL EQUIPMENT

WE WISH TO PURCHASE used xerography equipment for mammography examinations. Please call collect at (707) 468-9335.

WHOLESALE PRICES—Ask for your free Orthopaedic Supply Catalog. H & H Wholesale Orthopaedic Supply, Department WJ, 821 West Broadway, Room 103, Moses Lake, WA 98837, or call (509) 765-8076.

TREND IV EXAM TABLE. Tan upholstered, elec/hydraulic completely automatic, 26"-42" height, multiple positions. For all kinds of exams. Like new condition. $4225 OBO.

EXAM LIGHT—$95. For information, contact: Wayne R. Fiscus, DC, 260-F Main Street, Redwood City, CA 94063; (415) 368-8525.

SERVICES

1982-1983 FLEX STUDY GUIDE, personally prepared, compiled, and updated. Day One: 250 questions and answers, $60; Day Two: 250 questions and answers, $60; Day Three: 200 questions and answers plus 75 Patient Management Problems, $75. All Three Days available for $170. Send check to GSOP, PO Box 8165, Haledon, NJ 07508.

REAL ESTATE

ONCE IN A LIFETIME OPPORTUNITY! Medical/Dental complex now in planning and development stages. Located in beautiful large golf course subdivision in historic Sierra Foothills. Within one hour drive to Stockton or Sacramento. For information on lease/purchase or participation in planning or development of this facility, contact Richard A. Robyn, PO Box 1434, San Andreas, CA 95249; (800) 428-8808.

LOCUM TENENS

LOCUM TENENS SERVICE
WESTERN PHYSICIANS REGISTRY
. . . offers coverage for vacation or continuing education. To arrange coverage for your practice or to participate as temporary physician, contact: **Carol Sweig, Director, 1124 Ballena, Alameda, CA 94501; (415) 521-4110.**

PHYSICIAN INTERNIST Oakland (Alameda County): Ideal opportunity for experienced Physician Internist to work in culturally, socially, physically attractive San Francisco Bay Area. Part-time approximately twenty hours per week. Requirements include Board eligible or certified and good medical/conversational skills in Spanish preferred; salary negotiable. Please send curriculum viate with all inquiries to: La Clinica de la Raza, Attn: Personnel, 1515 Fruitvale Avenue, Oakland, CA 94601; (415) 532-0078.

FAMILY PRACTICE PHYSICIANS: Looking for physician interested in building a part-time practice and interested in having time to "smell the roses" as well. Submit CV to 300 South Market Boulevard, Apt. 3-C, Chehalis, WA 98532.

SITUATIONS WANTED

INTERNIST AVAILABLE: Board eligible internist educated Case Western Reserve seeks solo or group practice in Northern California. Available March 1985. Will also consider ER. Steven Wolinsky, MD, (201) 654-3649.

PRACTICES AVAILABLE

CALIFORNIA: Pathology, Radiology, Ophthalmology, OBG, Family, Internal, Surgery, Pediatric, Orthopedic, others. Contact: Mary Bradshaw, Practice broker/Recruiter, 21 Altamount Dr., Orinda, CA 94563; (415) 376-0762.

WELL ESTABLISHED FAMILY PRACTICE located in the San Joaquin Valley near Modesto. Office is well equipped and has an area of 1,800 square feet. Terms negotiable. Reply Box 6458, Western Journal of Medicine, 44 Gough St., San Francisco, CA 94103.

New Prescribing Information



Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of moderate to severe depression associated with moderate to severe anxiety.

Contraindications: Known hypersensitivity to benzodiazepines or tricyclic antidepressants. Do not use with monoamine oxidase (MAO) inhibitors or within 14 days following discontinuation of MAO inhibitors since hyperpyretic crises, severe convulsions and deaths have occurred with concomitant use; then initiate cautiously, gradually increasing dosage until optimal response is achieved. Contraindicated during acute recovery phase following myocardial infarction.

Warnings: Use with great care in patients with history of urinary retention or angle-closure glaucoma. Severe constipation may occur in patients taking tricyclic antidepressants and anticholinergic-type drugs. Closely supervise cardiovascular patients. (Arrhythmias, sinus tachycardia and prolongation of conduction time reported with use of tricyclic antidepressants, especially high doses. Myocardial infarction and stroke reported with use of this class of drugs.) Caution patients about possible combined effects with alcohol and other CNS depressants and against hazardous occupations requiring complete mental alertness (*e.g.*, operating machinery, driving).

***Usage in Pregnancy:* Use of minor tranquilizers during the first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.**

Since physical and psychological dependence to chlordiazepoxide have been reported rarely, use caution in administering Limbitrol to addiction-prone individuals or those who might increase dosage; withdrawal symptoms following discontinuation of either component alone have been reported (nausea, headache and malaise for amitriptyline; symptoms [including convulsions] similar to those of barbiturate withdrawal for chlordiazepoxide).

Precautions: Use with caution in patients with a history of seizures, in hyperthyroid patients or those on thyroid medication, and in patients with impaired renal or hepatic function. Because of the possibility of suicide in depressed patients, do not permit easy access to large quantities in these patients. Periodic liver function tests and blood counts are recommended during prolonged treatment. Amitriptyline component may block action of guanethidine or similar antihypertensives. Concomitant use with other psychotropic drugs has not been evaluated; sedative effects may be additive. Discontinue several days before surgery. Limit concomitant administration of ECT to essential treatment. See Warnings for precautions about pregnancy. Limbitrol should not be taken during the nursing period. Not recommended in children under 12. In the elderly and debilitated, limit to smallest effective dosage to preclude ataxia, oversedation, confusion or anticholinergic effects.

Adverse Reactions: Most frequently reported are those associated with either component alone: drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. Less frequently occurring reactions include vivid dreams, impotence, tremor, confusion and nasal congestion. Many depressive symptoms including anorexia, fatigue, weakness, restlessness and lethargy have been reported as side effects of both Limbitrol and amitriptyline. Granulocytopenia, jaundice and hepatic dysfunction have been observed rarely.

The following list includes adverse reactions not reported with Limbitrol but requiring consideration because they have been reported with one or both components or closely related drugs:

Cardiovascular: Hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias, heart block, stroke.

Psychiatric: Euphoria, apprehension, poor concentration, delusions, hallucinations, hypomania and increased or decreased libido.

Neurologic: Incoordination, ataxia, numbness, tingling and paresthesias of the extremities, extrapyramidal symptoms, syncope, changes in EEG patterns.

Anticholinergic: Disturbance of accommodation, paralytic ileus, urinary retention, dilatation of urinary tract.

Allergic: Skin rash, urticaria, photosensitization, edema of face and tongue, pruritus.

Hematologic: Bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia.

Gastrointestinal: Nausea, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue.

Endocrine: Testicular swelling and gynecomastia in the male, breast enlargement, galactorrhea and minor menstrual irregularities in the female, elevation and lowering of blood sugar levels, and syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Other: Headache, weight gain or loss, increased perspiration, urinary frequency, mydriasis, jaundice, alopecia, parotid swelling.

Overdosage: Immediately hospitalize patient suspected of having taken an overdose. Treatment is symptomatic and supportive. I.V. administration of 1 to 3 mg physostigmine salicylate has been reported to reverse the symptoms of amitriptyline poisoning. See complete product information for manifestation and treatment.

Dosage: Individualize according to symptom severity and patient response. Reduce to smallest effective dosage when satisfactory response is obtained. Larger portion of daily dose may be taken at bedtime. Single *h.s.* dose may suffice for some patients. Lower dosages are recommended for the elderly.

Limbitrol DS (double strength) Tablets, initial dosage of three or four tablets daily in divided doses, increased to six tablets or decreased to two tablets daily as required. Limbitrol Tablets, initial dosage of three or four tablets daily in divided doses, for patients who do not tolerate higher doses.

How Supplied: *Double strength (DS) Tablets*, white, film-coated, each containing 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt), and *Tablets*, blue, film-coated, each containing 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt)—bottles of 100 and 500; Tel-E-Dose® packages of 100; Prescription Paks of 50.

ROCHE®

ROCHE PRODUCTS INC.
Manati, Puerto Rico 00701

In moderate depression and anxiety

CLEARING: BOTH DEPRESSION AND ANXIETY...



Now

IN PLACE OF LIMBITROL 5-12.5 WRITE: **Limbitrol®**

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt) (IV)

IN PLACE OF LIMBITROL 10-25 WRITE: **Limbitrol® DS**

Each tablet contains 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) (IV)

ROCHE

Easier to remember...easier to prescribe

Please see summary of product information on reverse side.